

Cord Blood Donor Selection Guidelines (CB-DSG)

Edition 203 - 1 June 2010

Release 59 - 6 October 2026

Issue 1

Table of Contents

Guidelines

[Accident](#)

[Addiction and drug abuse](#)

[African trypanosomiasis](#)

[Age](#)

[Allergy](#)

[Anaemia](#)

[Animal bite, non-human](#)

[Ankylosing spondylitis \(AS\)](#)

[Anthrax](#)

[Antibiotic therapy](#)

[Arthritis](#)

[Asthma](#)

[Autoimmune disease](#)

[Babesiosis](#)

[Bacillus Calmette-Guérin \(BCG\)](#)

[Basal cell carcinoma \(BCC\)](#)

[Bleeding disorder](#)

[Blood pressure, high](#)

[Body piercing](#)

[Breast lump](#)

[Bronchitis](#)

[Brucellosis](#)

[Cardiac surgery](#)

[Cardiomyopathy](#)

[Cardiovascular disease \(CVD\)](#)

[Catarrh](#)

[Central nervous system \(CNS\) disease](#)

[Cervical dysplasia](#)

[Chickenpox](#)

[Chiropody](#)

[Chondromalacia](#)

[Cirrhosis](#)

[Clinical trials](#)

[Coeliac disease](#)

[Colostomy](#)
[Communication difficulties](#)
[Complementary therapy](#)
[Congo fever](#)
[Corneal transplant](#)
[Coronary thrombosis](#)
[Coronavirus infection](#)
[Deep vein thrombosis \(DVT\)](#)
[Dementia](#)
[Dental treatment](#)
[Dermatitis](#)
[Diabetes insipidus](#)
[Diabetes mellitus](#)
[Diarrhoea](#)
[Dilatation and curettage](#)
[Disabled mother](#)
[Disease of unknown aetiology](#)
[Diverticulosis](#)
[Drug treatment](#)
[Electrolysis](#)
[Emphysema](#)
[Endocarditis](#)
[Endometriosis](#)
[Epilepsy](#)
[Eye disease](#)
[Eye drops](#)
[Factor V Leiden](#)
[Fertility](#)
[Filariasis](#)
[Food allergy](#)
[Gall bladder disease](#)
[Giardiasis](#)
[Gilbert's syndrome](#)
[Glaucoma](#)
[Glucose-6-phosphate dehydrogenase \(G6PD\) deficiency](#)
[Glycogen storage disease \(GSD\)](#)
[Gout](#)
[Granuloma inguinale](#)
[Growth hormone \(GH\)](#)

[Guillain-Barré syndrome](#)
[Haematological disease](#)
[Haematuria](#)
[Haemochromatosis](#)
[Haemoglobin disorders](#)
[Haemolytic anaemia](#)
[Haemorrhoids](#)
[Headache](#)
[Heaf test](#)
[Healthcare worker](#)
[Henna painting](#)
[Hepatitis](#)
[Hepatitis A](#)
[Hepatitis B](#)
[Hepatitis C](#)
[Hepatitis E](#)
[Hepatitis of unknown origin](#)
[Hereditary elliptocytosis](#)
[Hereditary spherocytosis](#)
[Herpes simplex](#)
[Herpes zoster](#)
[Herpes, genital](#)
[Herpes, oral](#)
[Hormone replacement therapy \(HRT\)](#)
[Human immunodeficiency virus \(HIV\)](#)
[Human T-cell lymphotropic virus \(HTLV\)](#)
[Huntington's disease](#)
[Hydatid disease](#)
[Hydrocephalus](#)
[Hypnotics](#)
[Ileostomy](#)
[Immune thrombocytopenia](#)
[Immunisation](#)
[Immunisation, live](#)
[Immunisation, non-live](#)
[Immunoglobulin therapy](#)
[Immunosuppression](#)
[Infection, acute](#)
[Infection, chronic](#)

[Infection, general](#)
[Infection, tropical](#)
[Infectious diseases, contact with](#)
[Inflammatory bowel disease \(IBD\)](#)
[Inherited diseases](#)
[Inoculation injury](#)
[Irritable bowel syndrome \(IBS\)](#)
[Jaundice](#)
[Kidney disease](#)
[Laser treatment](#)
[Leishmaniasis](#)
[Leukaemia](#)
[Malaria](#)
[Malaria - contact in the UK](#)
[Malignancy](#)
[Mantoux test](#)
[Marfan syndrome](#)
[Measles](#)
[Meningitis](#)
[Mental health problems](#)
[Methicillin resistant staphylococcus aureus \(MRSA\)](#)
[Mitral valve prolapse](#)
[Mosquito-borne viruses](#)
[Mpox](#)
[Multiple sclerosis \(MS\)](#)
[Mumps](#)
[Muscular dystrophy](#)
[Myasthenia gravis \(MG\)](#)
[Myelodysplastic syndrome \(MDS\)](#)
[Myeloproliferative syndrome](#)
[Myocarditis](#)
[Ménière's disease](#)
[Neurofibromatosis \(NF\)](#)
[Neurosurgery](#)
[Night sweats](#)
[Non-specific urethritis \(NSU\)](#)
[Nonsteroidal anti-inflammatory drugs \(NSAIDs\)](#)
[Ocular surgery](#)
[Ocular tissue recipient](#)

[Operations](#)
[Organ donor](#)
[Organ recipient](#)
[Osteoarthritis](#)
[Osteomalacia](#)
[Osteomyelitis](#)
[Osteoporosis](#)
[Ovarian cyst](#)
[Paget's disease of bone](#)
[Painkillers](#)
[Parvovirus B19](#)
[Peptic ulcer](#)
[Perthes disease](#)
[Pituitary extract, human](#)
[Platelet disorders](#)
[Pleurisy](#)
[Pneumothorax](#)
[Poisoning](#)
[Polycythaemia](#)
[Porphyria](#)
[Post-viral fatigue syndrome](#)
[Pre- and post-exposure prophylaxis \(PrEP, PEP\) for HIV prevention](#)
[Pregnancy](#)
[Prion-associated diseases](#)
[Psoriasis](#)
[Pulmonary embolism \(PE\)](#)
[Pyrexia](#)
[Pyruvate kinase deficiency \(PKD\)](#)
[Q fever](#)
[Rabies](#)
[Radiation therapy](#)
[Radionuclides](#)
[Raynaud's syndrome](#)
[Recipients of normal human immunoglobulin](#)
[Renal colic](#)
[Respiratory disease](#)
[Retinitis pigmentosa \(RP\)](#)
[Rheumatic fever](#)
[Rheumatoid arthritis \(RA\)](#)

[Ringworm](#)
[Rubella](#)
[Sarcoidosis](#)
[Self-catheterisation](#)
[Sex worker](#)
[Sexually transmitted disease \(STD\)](#)
[Shingles](#)
[Sickle cell trait](#)
[Skin disease](#)
[Smallpox immunisation](#)
[Snake bite](#)
[South American trypanosomiasis](#)
[South American trypanosomiasis, risk of](#)
[Spina bifida](#)
[Spinal surgery](#)
[Splenectomy](#)
[Steroid therapy](#)
[Stroke](#)
[Surgery](#)
[Syphilis](#)
[Systemic lupus erythematosus \(SLE\)](#)
[Tamoxifen](#)
[Tetanus immunisation](#)
[Therapeutic venesection](#)
[Threadworms](#)
[Thrombocytosis](#)
[Thrombosis](#)
[Thrush, oral](#)
[Thrush, vaginal](#)
[Thyroid disease](#)
[Tissue and cell allograft recipients](#)
[Tissues safety](#)
[Toxoplasmosis](#)
[Transfusion](#)
[Travel](#)
[Trypanosoma cruzi infection](#)
[Tuberculosis \(TB\)](#)
[Turner syndrome](#)
[Vasculitis](#)

[Viral haemorrhagic fever \(VHF\)](#)

[Vitamin treatment](#)

[Warts](#)

[Warts, genital](#)

[Weight loss medication](#)

[West Nile Virus \(WNV\)](#)

[Whooping cough](#)

[Wilson's disease](#)

[Xenotransplantation](#)

[Xenotropic murine leukemia virus-related virus \(XMRV\)](#)

[Yaws](#)

Using these guidelines

[Using these guidelines](#)

Updates

[Updates](#)

Appendices

[Appendix 1: Medical criteria for the withdrawal of donations following information received after donation](#)

[Appendix 2: Immunisations](#)

Accident

Cord Blood

Essential information

Includes

Trauma

Obligatory

Must not donate if:

1. Not recovered.
2. Still under follow-up.
3. Has a plaster-cast.

Supporting information

See if relevant

- [Neurosurgery](#)
- [Surgery](#)
- [Tetanus immunisation](#)
- [Transfusion](#)

Additional information

An unhealed wound or sore is a risk for bacteria entering the blood. Bacteria in blood can be a serious threat to anybody receiving stem cells. This is because the bacteria can multiply to dangerous levels.

A plaster-cast can hide a wound or sore.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Addiction and drug abuse

Cord Blood

Essential information

Obligatory

Must not donate if:

1. The mother has injected, or been injected with, drugs in the past 12 months.
2. The mother is adversely affected by any drug, including alcohol, which may affect the process of obtaining valid consent.
3. The mother has injected, been injected with, or taken non-parenteral chemsex drugs in the past 3 months. See [Tissues safety](#).

Discretionary

1. Accept if mother has not injected, or been injected with, other non-prescription drugs (other than drugs of addiction), such as bodybuilding drugs or injectable tanning agent within the past 3 months.
2. Accept if mother has not injected, or been injected with, drugs of addiction within the last 12 months.
3. If mother has not injected or been injected with drugs of addiction within the last 3 months, refer to Designated Clinical Support Officer. The donation may be accepted with individual risk assessment. See **Additional information** below.
4. May be acceptable if injected drugs were prescribed by the mother's physician for a condition that would not lead to exclusion.
5. Previous use of non-parenteral drugs does not necessarily require exclusion.

Supporting information

See if relevant

- [Tissues safety](#)

Additional information

Injecting drugs has been linked with the passing on of many infections, including hepatitis and HIV. It can be many years before any infection shows itself. Former drug users often do not realise that they can still pass infection on to others many years after they last used drugs themselves. The deferral periods specified above may be reduced by doing individual risk assessment if the risk of acquiring an infectious disease may be outweighed by the risk of delaying a lifesaving transplantation. This guidance presumes that a validated NAT test for HIV, HBV and HCV is negative; if this test is stopped for any reason, the guidance will change

Anyone obviously affected by alcohol or other drugs that can affect the mind, cannot give valid consent or fully understand why they are being asked certain questions.

Reason for change: Obligatory section updated as a part of the implementation of recommendations from the FAIR III report, including addition of chemsex drugs.

Version details: CB-DSG Edition 203 Release 51 (15 November 2023)

African trypanosomiasis

Cord Blood

Also known as: sleeping sickness

Essential information

Obligatory  Must not donate.

*Reason for change: 'Sleeping sickness' added as an 'Also known as' term.
Version details: CB-DSG Edition 203 Release 57 (1 May 2026)*

Age

Cord Blood

Essential information

Obligatory	Must not donate if: Mother is under 17 years of age.
------------	--

Supporting information

Additional information	This takes account of national laws on age of consent.
------------------------	--

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Allergy

Cord Blood

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Steroid therapy](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Anaemia

Cord Blood

Essential information

Obligatory

Must not donate if:

Mother or father homozygous or heterozygous for inherited haemoglobin disorder or enzymopathy.

Inform Transplant Centre if:

Cells are from a baby that has an inherited disorder.

Discretionary

1. If:

- a. The cord blood is tested for the relevant condition and is shown to be unaffected, accept.
- b. For X-linked disorders, father affected and male baby, accept. If mother affected and female baby, accept.
- c. For non-X-linked disorders, baby is heterozygous (trait), accept.

2. History of anaemia:

This should be assessed regarding its cause, current status and what treatment has been received.

3. Iron deficiency:

If not under investigation and the underlying cause is not a reason to exclude, accept.

4. Other types:

Accept or exclude according to the guidelines.

5. In other cases:

Refer to a Designated Clinical Support Officer.

Supporting information

See if relevant

- [Haemoglobin disorders](#)
- [Haemolytic anaemia](#)
- [Malignancy](#)

If treated with blood components or products or by plasma exchange or filtration:

- [Transfusion](#)

Additional information

A successful transplant will mean the recipient will produce the same blood as the donor. This would be unacceptable for a homozygous (major) form of blood disorder but would probably be acceptable for a heterozygous (minor form, or trait).

By informing the transplant centre, details can be passed on to the person receiving the transplant. This can avoid unnecessary problems in the future. For example, searching for the cause of small red cells or anaemia in a person who has had a transplant from a donor with thalassaemia minor (trait).

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Animal bite, non-human

Cord Blood

Essential information

Includes

Snake bite

Obligatory

Must not donate if:

1. Ever bitten by a non-human primate.
2. Any wound is infected or not healed.
3. Less than 12 months since bitten anywhere in the world by a bat or by any other mammal outside of the British Isles (UK and Ireland).
4. The donor is not fully recovered.

Supporting information

See if relevant

- [Infection, general](#)
- [Inoculation injury](#)
- [Rabies](#)
- [Surgery](#)

Additional information

Being bitten by a non-human primate should result in permanent deferral. Risks include simian T-lymphotropic virus, herpes B, simian foamy virus and other as yet unknown viruses. Non-human primates include chimpanzees, gorillas, orangutans, gibbons, monkeys (old and new world), tarsiers, lemurs and lorises.

Animal bites may result in many different infections. Allowing all wounds to heal and for any obvious infection to have resolved should avoid problems.

As well as local care of the bite, donors may receive other treatments such as antibiotics or immunisation; these may affect the donor's eligibility. Bites from venomous snakes can cause extensive local tissue damage that can take a long time to heal and may require surgery. Depending on the species of biting snake, their venom can cause problems with blood clotting and, in severe cases, require transfusion of blood components (e.g. plasma or cryoprecipitate).

Rabies, and similar diseases, have long incubation periods and do not show as a wound infection. There is no evidence that these infections have ever been transmitted through a cord blood donation. These diseases appear to be confined to the nervous system during their incubation periods. There is evidence that they have been transmitted through organ, tissue and ocular transplants. For this reason, there are different rules for material that may contain nervous system tissue.

Anyone who has been in unusual contact with a bat, such as handling a sick or injured bat, or woken to find that a bat has been with them while asleep, should be considered at risk of rabies. Bat bites are usually insignificant and easily overlooked. Merely being in a place where bats roost is not considered a risk.

Reason for change: Guidance on snake bites is now included in this entry. A reminder to assess treatments beyond local wound care has been added to the 'Additional information' section. The 'See if relevant' links have been updated.
Version details: CB-DSG Edition 203 Release 59 (6 October 2026)

Ankylosing spondylitis (AS)

Cord Blood

Essential information

Obligatory	See: Autoimmune disease
Discretionary	Accept.

Reason for change: A link to 'Autoimmune disease' added.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Anthrax

Cord Blood

Scenarios

Infection

Obligatory

See: [Infection, acute](#)

Exposure

Discretionary

Even if on prophylactic antibiotics, accept.

Additional information

Anthrax infection most commonly affects the skin through direct contact with infected material such as animal hides. If spores have been inhaled, there is no evidence that there is any spread to the bloodstream until the person has developed signs of infection. For this reason, it is considered safe to accept exposed mothers provided they have not shown signs of infection, even if they have been given prophylactic antibiotics.

Immunisation

Obligatory

See: [Immunisation, non-live](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Antibiotic therapy

Cord Blood

Essential information

Obligatory See: [Infection, general](#)

Supporting information

Additional information Treatment with antibiotics is not of itself a reason for deferral but the reason for the treatment may be. When treatment is being given to prevent infection, rather than to treat it, see if there is a relevant [entry](#). If not, discuss with a Designated Clinical Support Officer.

*Reason for change: Additional Information has been added for clarity.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Arthritis

Cord Blood

Supporting information

See if relevant

- [Ankylosing spondylitis](#)
- [Autoimmune disease](#)
- [Osteoarthritis](#)
- [Psoriasis](#)
- [Rheumatoid arthritis](#)

*Reason for change: A link has been added for Autoimmune Disease.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Asthma

Cord Blood

Essential information

Obligatory	Must not donate if: Taking, or has completed, oral or parenteral steroids within the last 7 days.
------------	---

Supporting information

See if relevant	• Infection, general • Steroid therapy
Additional information	Steroid therapy can hide the signs and symptoms of infection. Stem cells from an infected donor could be dangerous to the person receiving them.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Autoimmune disease

Cord Blood

Essential information

Obligatory

Must not donate if:

The mother has needed treatment to suppress the condition in the last 12 months.

Supporting information

See if relevant

If treated with immunoglobulin or plasma exchange or filtration:

- [Transfusion](#)

Additional information

Treatment to suppress the condition may be with steroids, immunosuppressive drugs, antimetabolites, antibodies directed against parts of the immune system as well as other therapies. These will affect the mother's immune system. This may make her more susceptible to certain types of infection and also will make some infections more difficult to diagnose.

Reason for change: Additional Information has been added to clarify treatment that may have been used to suppress the condition. Autoimmune disease will not be transmitted through cord blood or amniotic membrane.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Babesiosis

Cord Blood

Essential information

Obligatory	Must not donate.
------------	------------------------------

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Bacillus Calmette-Guérin (BCG)

Cord Blood

Essential information

Obligatory

See: [Immunisation, live](#)

Must not donate if:

Immunised in this pregnancy.

Supporting information

Additional information

BCG is an immunisation with live bacteria. We do not want to pass BCG, or other infections, on to people receiving donated material.

Reason for change: Entry carried over from previous Edition.

Basal cell carcinoma (BCC)

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Still receiving treatment.
2. Any wound has not healed.

Supporting information

Additional information

Although basal cell carcinoma is a form of cancer, it only spreads locally. As it does not spread by the blood stream, it is not a risk to people receiving donated material.

An unhealed wound is a risk for bacteria entering the blood. Bacteria can be a serious threat to anybody receiving donated material. This is because the bacteria can multiply to dangerous levels.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Bleeding disorder

Cord Blood

Essential information

Includes

Coagulation factor deficiencies:

- Factor I (one) fibrinogen deficiency (afibrinogenaemia, hypofibrinogenaemia)
- Factor II (two) prothrombin deficiency
- Factor V (five) deficiency
- Factor VII (seven) deficiency
- Factor VIII (eight) deficiency (haemophilia A)
- Factor IX (nine) deficiency (haemophilia B, Christmas disease)
- Factor X (ten) deficiency
- Factor XI (eleven) deficiency
- Factor XIII (thirteen) deficiency
- Von Willebrand disease (types 1, 2 and 3)

Excludes

Platelet disorders – see [Platelet disorders](#)

Individuals who received coagulation factor concentrates (including prothrombin complex concentrates):

- To treat and prevent the coagulopathy associated with trauma and/or massive transfusion
- To reverse the effect of anticoagulants such as warfarin (see [Transfusion](#))

Scenarios

Affected individuals and carriers

Obligatory

Must not donate if:

1. Diagnosed with haemophilia A (Factor VIII deficiency), haemophilia B (Factor IX deficiency), type 2 von Willebrand disease, type 3 von Willebrand disease.
2. The donor has received a transfusion since 1 January 1980.
3. The donor has ever:
 - a. Received coagulation factor concentrates, including blood-derived and recombinant products, and/or
 - b. Received or is currently on treatment to reduce or prevent excessive bleeding (e.g. desmopressin, tranexamic acid, oral contraceptive pill and similar hormone therapies).
4. The donor has required or been advised they will require prophylactic treatment for surgery, dental treatment, or for any other procedure.
5. There is a history of excessive bleeding or bruising.
6. The donor is requiring monitoring and/or follow-up.
7. There is associated organ involvement (e.g. liver damage).
8. For acquired disorders, the underlying cause or treatment precludes donation (e.g. malignancy, monoclonal antibody therapy).

Discretionary

If the donor has type 1 von Willebrand disease and:

1. Has not received a transfusion since 1 January 1980, and

2. Has never received any type of coagulation factor treatment, and
3. Has never received any other treatment to reduce or prevent excessive bleeding, and
4. Has not received or been advised that they will require prophylactic treatment, and
5. Has never had any excessive bleeding or bruising, and
6. Is not requiring monitoring or follow-up, and
7. The underlying cause and/or treatment does not preclude donation, accept.

If the donor is a carrier of a coagulation factor deficiency, and:

1. Has not received a transfusion since 1 January 1980, and
2. Has never received any type of coagulation factor treatment, and
3. Has never received any other treatment to reduce or prevent excessive bleeding, and
4. Has not received or been advised that they will require prophylactic treatment, and
5. Has never had any excessive bleeding or bruising, and
6. Is not requiring monitoring or follow-up, accept.

See if relevant

- [Autoimmune disease](#)
- [Malignancy](#)
- [Platelet disorders](#)
- [Transfusion](#)

Additional information

Coagulation factor deficiencies can be inherited or can be acquired, associated with haematological, neoplastic, cardiovascular, liver or autoimmune disease.

Some deficiencies cause significant bleeding, either spontaneously or in response to even minimal trauma or minor procedures. Individuals will have been assessed and advised about their condition and bleeding risk. They may have received treatment or been informed regarding the need for treatment in the future. The donor may have also been provided with a Bleeding Disorder Information Card.

Some people with the carrier state (trait) may be at risk of bleeding (symptomatic carriers). The diagnosis of the milder forms or carrier status of coagulation factor deficiencies may arise from family screening, or through testing during investigation for menorrhagia (heavy periods), or bleeding during pregnancy or childbirth.

If someone has had problems with abnormal bleeding or bruising, they may be at increased risk of complications from donation.

The guidance contained in this entry is not intended for use for donors without a coagulation factor deficiency, for example for someone who may have taken tranexamic acid for heavy periods due to an underlying gynaecological cause.

The current International Society on Thrombosis and Haemostasis (ISTH) classification recognises three types of von Willebrand disease. Type 1 is a partial quantitative deficiency of von Willebrand factor and is typically a milder form; the levels of von Willebrand factor may overlap with the levels found in unaffected individuals. More severe effects are usually seen with von Willebrand disease types 2 and 3. Care should be taken to determine the type of von Willebrand disease, as only donors with type 1 are potentially eligible.

Reason for change: Entry expanded to clarify which affected individuals may or may not donate. The 'Affected Individuals' scenario has been renamed 'Affected Individuals and Carriers'. The deferral of family members, carers or sexual partners of individuals treated with blood-derived coagulation factor concentrates has been removed.

Version details: CB-DSG Edition 203 Release 59 (6 October 2026)

Blood pressure, high

Cord Blood

Also known as: hypertension

Essential information

Obligatory

If the mother has had severe hypertension in pregnancy:
Refer to a Designated Clinical Support Officer.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Body piercing

Cord Blood

Essential information

Includes	Derma-rolling, ear and body piercing, permanent and semi-permanent makeup, tattooing (including memorial tattoos), platelet rich plasma (PRP) facials, ritual self-flagellation.
Obligatory	Must not donate if: Less than 3 months after last piercing.
Discretionary	Piercings performed within the UK in a commercial setting: Accept. Piercings performed outside the UK or within the UK in an unlicensed non-commercial premises more than 3 months ago: Accept. Painting, stencilling or transfers applied to the skin without piercing: Accept.

Supporting information

Additional information	Under all current legislation, it is a criminal offence to trade without registration (licensing) or to be in breach of the relevant bylaws. Similar provisions are in place in Scotland in the Civic Government (Scotland) Act 1982 (Licensing of Skin Piercing and Tattooing) Order 2006. Some London boroughs also require a 'special treatment' license. It is expected that all premises will follow infection control processes including using single needles for treatments. In the UK, local authorities are responsible for regulating and monitoring businesses providing semi-permanent skin colouring procedures (micropigmentation, semi-permanent make-up and temporary tattooing). The focus of legislation covering local authorities in England, Wales and Northern Ireland (Local Government (Miscellaneous Provisions) Act 1982) is on minimising infection risks using compulsory registration of practitioners and premises and optional powers to make bylaws. For piercings performed outside the UK or within the UK in an unlicensed, non-commercial establishment less than 3 months ago, the donor may only be accepted following documented individual risk assessment and discussion with the transplant centre if the risk of delaying transplant outweighs the risk of transmission of infections. Piercing has passed infection from person to person. Waiting 3 months helps to ensure that the infections tested for by the UK Blood and Tissues Services will be picked up. Platelet rich plasma (PRP) facials (also known as 'vampire facials') have been associated with HIV transmission. Ritual self-flagellation is carried out by some religious groups. The practice includes beating or flogging oneself with sharp objects. It may be associated with exposure to blood from other participants, either directly or through contamination of shared equipment. This guidance presumes that a validated NAT test for HIV, HBV and HCV is
------------------------	---

negative; if this test is stopped for any reason, the guidance will change.

Reason for change: To add Derma-rolling, ear and body piercing, tattooing (including memorial tattoos), platelet rich plasma (PRP) facials and ritual self-flagellation to the entry and to add information regarding PRP facials and ritual self-flagellation.
Version details: CB-DSG Edition 203 Release 43 (16 March 2022)

Breast lump

Cord Blood

Essential information

Obligatory

See: [Surgery](#)

Must not donate if:

1. Malignant.
2. Not fully investigated and cleared of malignancy.

Supporting information

See if relevant

- [Malignancy](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Bronchitis

Cord Blood

Scenarios

Acute bronchitis

Obligatory

See: [Infection, acute](#)

Chronic bronchitis

See if relevant

- [Infection, general](#)
- [Steroid therapy](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Brucellosis

Cord Blood

Also known as: undulant fever

Essential information

Obligatory | **Must not donate.**

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Cardiac surgery

Cord Blood

Supporting information

See if relevant

- [Cardiovascular disease](#)
- [Endocarditis](#)
- [Surgery](#)
- [Transfusion](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Cardiomyopathy

Cord Blood

Essential information

Obligatory	Must not donate if: Not recovered from infective causes.
------------	---

Reason for change: This is a new entry.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Cardiovascular disease (CVD)

Cord Blood

Supporting information

See if relevant

- [Cardiomyopathy](#)
- [Endocarditis](#)
- [Myocarditis](#)

Reason for change: Additional links have been added.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Catarrh

Cord Blood

Scenarios

Acute catarrh

Obligatory See: [Infection, acute](#)

Chronic catarrh

See if relevant • [Infection, general](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Central nervous system (CNS) disease

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Dementia.
2. History of CNS disease of unknown or suspected infective origin, e.g. multiple sclerosis (MS), optic neuritis, clinically isolated syndrome, transverse myelitis, Creutzfeldt-Jakob disease (CJD).
3. Neurodegenerative conditions of unknown aetiology (e.g. Parkinson's disease).

Discretionary

1. Individuals who have had Bell's palsy more than 4 weeks ago and have discontinued any treatment for the condition for at least 7 days, even if they have residual paralysis, accept.
2. If a definite diagnosis of transient global amnesia has been made, accept.
3. If the cause of the disease is not established, refer to Designated Clinical Support Officer.

Supporting information

See if relevant

- [Neurosurgery](#)
- [Prion-associated diseases](#)
- [Rabies](#)

Additional information

Often the exact cause of a degenerative brain condition only becomes known after death. For this reason, when there is any doubt as to the underlying cause of a brain condition, it is considered safest not to accept a donation. It is thought that degenerative brain disease in the form of variant Creutzfeldt-Jakob disease (vCJD) has been transmitted by blood transfusion.

Transient global amnesia is a temporary and isolated disorder of memory. Affected individuals are usually over 50 years of age and there is an association with migraine. There is no association with cerebrovascular disease.

Reason for change: To clarify that CNS disease of unknown origin, and clinically isolated syndrome, are reasons for obligatory deferral and to permit individual risk assessment where appropriate.

Version details: CB-DSG Edition 203 Release 29 (24 April 2018)

Cervical dysplasia

Cord Blood

Also known as: cervical intraepithelial neoplasia, CIN

Essential information

Obligatory

Must not donate if:

1. Undergoing investigation or treatment.
2. Diagnosed with invasive cervical carcinoma.

Discretionary

1. If the donor had colposcopy treatment for abnormal cervical cells and has been discharged to routine screening, accept. It is not necessary to wait for a normal smear result before donating.
2. If only having regular review of smears, accept.

Supporting information

Additional information

Cervical screening includes testing for high risk human papillomavirus (HR-HPV). Women who are positive for HR-HPV may be called for routine smear tests at more frequent intervals. They can donate, provided they are not undergoing other tests or awaiting colposcopy investigation.

Women with abnormal cells on a smear test are triaged according to their risk of developing cervical carcinoma. Women at higher risk will be referred for investigation and treatment via colposcopy.

Abnormalities identified at colposcopy include cervical intraepithelial neoplasia (CIN, Grades 1-3) and cervical glandular intraepithelial neoplasia (CGIN). CIN-3 is also known as cervical carcinoma in situ. By definition, patients with CIN or CGIN do not have invasive cervical carcinoma, so can be accepted once treated, fully healed and discharged. There is no need to wait for the results of their next routine smear, usually at 6 months post treatment, unless the donor has been advised that follow-up will be necessary at the colposcopy clinic.

Reason for change: Updated to clarify the scope of entry, when a donor can be accepted after treatment for cervical dysplasia and the significance of HR-HPV testing.

Version details: CB-DSG Edition 203 Release 43 (16 March 2022)

Chickenpox

Cord Blood

Scenarios

Affected individual

Obligatory

See: [Infection, acute](#)

Must not donate if:

Has had chickenpox or shingles during pregnancy.

Contact with an affected individual

Obligatory

See: [Infectious diseases, contact with](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Chiropody

Cord Blood

Also known as: podiatry

Essential information

Obligatory	Must not donate if: There are open wounds or infection.
------------	---

Supporting information

See if relevant	For fungal infection: Infection, chronic
-----------------	--

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Chondromalacia

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Cirrhosis

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Complicated by hepatoma.
2. Infectious or autoimmune cause.

Discretionary

If the cause is genetic, accept.

Supporting information

See if relevant

- [Addiction and drug abuse](#)
- [Autoimmune disease](#)
- [Malignancy](#)

Reason for change: Additional links have been added.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Clinical trials

Cord Blood

Essential information

Obligatory

Must not donate if:

Participating in a clinical trial. This includes the use of drugs of any kind (e.g. oral, injected, parenteral, transcutaneous) and applies to healthy individuals participating as volunteers, for example in 'phase 1' clinical trials.

Discretionary

If a Designated Clinical Support Officer has examined and agreed the trial protocol, accept.

Supporting information

See if relevant

- [Complementary therapy](#)
- [Transfusion](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Coeliac disease

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Colostomy

Cord Blood

Essential information

Obligatory	Must not donate if: For malignancy or inflammatory bowel disease.
Discretionary	If the reason for the colostomy is not of itself a reason to exclude and the stoma is healthy, accept.

Supporting information

See if relevant	Surgery
-----------------	---

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Communication difficulties

Cord Blood

Essential information

Obligatory

1. All mothers must:

- a. Fully understand the donation process.
- b. Give their informed consent to the process and to the testing of their blood for diseases that may affect the suitability of their baby's stem cells/tissues for use.

2. Third party interpreters:

If they are to be present at any part of the selection procedure where there is an exchange of confidential information between the mother and the qualified healthcare professional, they must:

- a. Understand the importance of providing an accurate and truthful translation of the information provided, to enable the tissue/cell establishment to comply with regulatory requirements
- b. Not be personally known to the mother.
- c. Fully understand their duty of confidentiality and the confidential nature of any information obtained from the donor.

Supporting information

See if relevant

- [Disabled mother](#)

Additional information

The UK Blood and Tissue Services are aware of their duties under Race Relations and Disability Discrimination Legislation and will, whenever and wherever reasonable, try to provide facilities for individuals whose first language is not English, or who have other difficulties in communicating. Potential donors with such difficulties are advised to seek advice from their local [Blood and Tissue Service](#) before offering to donate stem cells to see if their needs can be met.

Every mother must:

1. Be provided with accurate educational materials, which are written in terms which can be understood by members of the general public.
2. Complete a health and medical history questionnaire and undergo a personal interview performed by a healthcare professional.
3. Provide written informed consent to proceed with the donation process which must be countersigned by the qualified healthcare professional responsible for obtaining the health history.

A qualified healthcare professional may assist a mother in the completion of the health and medical history questionnaire and in understanding the consent statement and any other information provided by the Tissue Service. To facilitate comprehension, it is permissible to use alternative formats (e.g. a language other than English, audio, computer, Braille) for the information leaflets, the health and medical history questionnaire and consent statements. The mother must be able to clearly demonstrate they have understood this material. At present, there is no standardised way of assessing comprehension so this will be a personal judgement made by the healthcare professional.

Use of third party interpreters:

It is permissible for any third party to act as an enabler by helping to reassure the mother and to assist in establishing effective communication between the mother and the healthcare professional. The third party must not however be present during any exchange of confidential information, unless they are not personally known to the mother and understand the need to accurately and truthfully communicate all the information, including personal and confidential information, provided by the person giving consent. Confidential parts of the process include the evaluation of the health and medical history questionnaire, the medical interview and the obtaining of valid consent. Any third party, with the permission of the mother, may accompany the mother through other parts of the donation process that do not include the exchange of confidential information.

Rationale:

There is concern that the use of third parties during any exchange of confidential information between the mother and the healthcare professional may compromise the confidentiality of the mother and the safety of any donated material. Interpreters are often part of a close community, or a family member, and this may inhibit or embarrass the mother in any confidential exchange of information. This may result in the non-disclosure of sensitive information that could affect the individual's eligibility to donate. If a third party is not fully aware of the need to accurately and truthfully communicate all the information, including personal and confidential information, provided by the person giving consent, this may make the interpretation of information incomplete and potentially put both the mother and the donated material at risk. There is also a requirement to communicate the results of any testing performed by the Tissue Services that may be of relevance to the mother or her baby's health in a way that protects their confidentiality. The continuing availability of an independent interpreter, to maintain confidentiality, should be taken into account when deciding if an individual mother may be accepted.

Reason for change: 1. To clarify that interpreters and translators do not need to understand all the regulatory requirements of the Human Tissue Act, but are aware of the importance of providing a truthful and accurate translation to enable the tissue/cell establishment to comply with regulatory requirements. 2. To clarify that interpreters and translators have a duty of confidentiality. Version details: CB-DSG Edition 203 Release 19 (17 March 2015)

Complementary therapy

Cord Blood

Essential information

Obligatory

1. **Must not donate if:**
The condition for which treatment was given is not acceptable.
2. **Therapies involving penetration by needles or other invasive procedures:**
Must not donate if:
Less than 3 months from completing treatment.

Discretionary

1. If oral or topical complementary medicines only and reason for which treatment was given is acceptable, accept.
2. For all other therapies involving penetration by needles or other invasive procedures:

Performed within the NHS:
If performed by a suitably qualified NHS healthcare professional on NHS premises, accept.

Performed outside of the NHS:
 - a. If performed by a Qualified Health Care Professional registered with the General Medical Council (GMC), Nursing and Midwifery Council (NMC), General Dental Council (GDC), The General Chiropractic Council (GCC), The General Optical Council (GOC), The General Osteopathic Council (GOsC), General Pharmaceutical Council (GPhC), Pharmaceutical Society of Northern Ireland (PSNI), or The Health and Care Professions Council (HCPC) (which regulates: Arts therapists, Biomedical Scientists, Chiropodists/ Podiatrists, Clinical Scientists, Dieticians, Hearing Aid Dispensers, Occupational Therapists, Operating Department Practitioners, Orthoptists, Paramedics, Practitioner Psychologists, Physiotherapists, Prosthetists and Orthotists, Radiographers, and Speech and Language Therapists), accept.
 - b. Treatments performed within commercial premises in the UK, accept.
 - c. If performed within unlicensed, non-commercial premises in the UK, or for any treatment performed outside the UK more than 3 months ago, accept.

Supporting information

Additional information

Equipment that has been reused has passed infection from person to person. Therapists who are subject to discipline from statutorily constituted professional authorities are unlikely to re-use needles.

Commercial premises may be based in shops and clinics and also include operators running an acupuncture business from a residential premise such as their own homes. Under all current legislation, it is a criminal offence to trade as an acupuncturist without registration (licensing) or to be in breach of the relevant bylaws. Similar provisions are in place in Scotland in the Civic Government (Scotland) Act 1982 (Licensing of Skin Piercing and Tattooing) Order 2006. Some London boroughs also require a 'special treatment' license. It is expected that all premises will follow infection control processes including using single needles for treatments.

In the UK, local authorities are responsible for regulating and monitoring businesses providing tattooing, cosmetic piercings, semi-permanent skin colouring (micropigmentation, semi-permanent make-up and temporary tattooing), electrolysis and acupuncture. The focus of legislation covering local authorities in England, Wales and Northern Ireland (Local Government (Miscellaneous Provisions) Act 1982) is on minimising infection risks using compulsory registration of practitioners and premises and optional powers to make bylaws.

Healthcare professionals registered with statutory body may not need to register with the local authority as their statutory body is responsible for their regulation.

This guidance presumes that a validated NAT test for HIV, HBV and HCV is negative; if this test is stopped for any reason, the guidance will change.

When there is any doubt about infection being passed on, waiting 3 months means infections are more likely to be picked up by the tests used by UK Blood and Tissue Services.

Reason for change: The regulatory organisations for Pharmacists in the UK have been added. The HCPC ceased to be the regulatory authority for Social Workers in England in 2019. The list of health and care professionals regulated by the HCPC has been amended.

Version details: CB-DSG Edition 203 Release 42 (22 February 2022)

Congo fever

Cord Blood

Essential information

Obligatory

Must not donate if:

Less than 12 months following recovery or from return to the UK, if occurred abroad.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Corneal transplant

Cord Blood

Essential information

Obligatory Must not donate.

Supporting information

See if relevant

- [Prion-associated diseases](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Coronary thrombosis

Cord Blood

Essential information

Includes Heart attack, myocardial infarct.

Discretionary Accept.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Coronavirus infection

Cord Blood

Also known as: COVID-19

Essential information

Includes COVID-19 disease (due to infection with SARS-CoV-2 virus, previously known as Novel Coronavirus or 2019-nCoV).

Supporting information

See if relevant

- [Immunisation, non-live](#)
- [Infection, acute](#)
- [Infectious diseases, contact with](#)

Additional information

Common coronaviruses cause colds and respiratory tract infections but are not considered a risk for tissue transplant recipients. Since 2002, there have been outbreaks in humans of new strains of coronavirus, associated with severe pulmonary infections and mortality rates of 10–35% (e.g. SARS and MERS).

COVID-19 is an illness characterised by respiratory symptoms, including coughing and breathlessness, and fever. It is caused by infection with a newly identified coronavirus, SARS-CoV-2. Its full pathogenesis remains unknown but individuals with certain underlying chronic conditions, the elderly and immunocompromised individuals are at risk of more severe disease.

Some persons with SARS-CoV-2 infection may be asymptomatic. It is possible that they may have undergone testing for occupational health reasons (for example). Routine screening of living asymptomatic tissue/cell donors is not necessary. They are likely to have been screened before hospital admission for a planned procedure as per hospital policy.

There is no evidence at present that SARS-CoV-2 can be transmitted by tissue/cell transplantation and therefore these measures are considered to be precautionary.

Post donation illness Donors must be provided with information about contacting the tissue establishment if they develop any illness within 14 days after donation.

Scenarios

Person with confirmed symptomatic COVID-19

Obligatory	Must not donate if: Less than 7 days since resolution of symptoms.
Discretionary	If more than 7 days have passed since resolution of symptoms, and the donor remains well, accept.

Person with confirmed SARS-CoV-2 without symptoms

Obligatory	Must not donate if: Less than 7 days since confirmation of infection by positive results in a diagnostic test.
Discretionary	If more than 7 days have passed since confirmation of infection by positive results in a diagnostic test, accept.

See **Additional information** below.

Person with suspected COVID-19

Obligatory

Must not donate if:

Less than 14 days since resolution of symptoms.

Discretionary

1. If testing was not performed:

- a. If more than 14 days have passed since resolution of symptoms, and the donor remains well, accept.
- b. If more than 7 days but less than 14 days, See [Infection, acute](#).

OR

2. If testing was performed, and COVID-19 has been ruled out as a clinical diagnosis, see [Infection, acute](#).

*Reason for change: Delete outdated information in the definition section, and 'additional information' section.
Version details: CB-DSG Edition 203 Release 52 (15 November 2023)*

Deep vein thrombosis (DVT)

Cord Blood

Essential information

Discretionary If the underlying cause does not exclude, accept.

Supporting information

See if relevant • [Malignancy](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Dementia

Cord Blood

Essential information

Obligatory  Must not donate.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Dental treatment

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Less than 7 days since root canal treatment, dental capping or having a tooth removed.
2. Less than 24 hours since a filling, scale and polish or other superficial treatments.
3. All wounds are not healed.
4. There is any infection.

Discretionary

If inspection or dental impressions only, accept.

Supporting information

See if relevant

- [Infection, general](#)
- [Surgery](#)

Additional information

Dental extractions and other treatments can result in bacteria getting into the blood stream. The waiting times after treatment are to allow healing and for any bacteria that have entered the blood stream to be cleared.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Dermatitis

Cord Blood

Essential information

Obligatory

Must not donate if:

Mother has infected perineal dermatitis.

Supporting information

See if relevant

- [Allergy](#)
- [Infection, general](#)
- [Steroid therapy](#)

Reason for change: To add a link to Alitretinoin.

Version details: CM-DSG Edition 203 Release 16 (31 March 2014)

Diabetes insipidus

Cord Blood

Essential information

Discretionary If the underlying cause does not exclude, accept.

Supporting information

See if relevant • [Neurosurgery](#)

Reason for change: Entry carried over from previous Edition.

Diabetes mellitus

Cord Blood

Also known as: type 1 and type 2 diabetes, sugar diabetes

Essential information

Obligatory	Must not donate if: Uncontrolled infection.
Discretionary	Accept.

Supporting information

See if relevant

- [Infection, general](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Diarrhoea

Cord Blood

Essential information

Includes Diarrhoea and vomiting (D&V), enterocolitis, food poisoning, gastric flu, gastroenteritis.

Obligatory

Must not donate if:

1. Chronic or associated with inflammatory bowel disease.
2. Less than 2 weeks since full recovery.

Supporting information

See if relevant

- [Infection, general](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Dilatation and curettage

Cord Blood

Essential information

Obligatory

See: [Surgery](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Disabled mother

Cord Blood

Essential information

Obligatory

1. All mothers must:

- a. Fully understand the donation process.
- b. Give their informed consent to the process and to the testing of their blood for diseases that may affect the suitability of their baby's stem cells/tissues for use.

2. Third party interpreters:

If they are to be present at any part of the selection procedure where there is an exchange of confidential information between the mother and the qualified healthcare professional, they must:

- a. Understand the requirements of the Human Tissue Act relevant to the donation process.
- b. Not be personally known to the mother.

Discretionary

Mothers with difficulty in reading:

Ensure by questioning the mother that they:

1. Understand and fully complete the tick-box questionnaire.
2. Give valid consent to donation and to the testing of their blood for diseases that may affect its suitability for use.

Supporting information

See if relevant

- [Self-catheterisation](#)
- [Spina bifida](#)

Additional information

The UK Blood and Tissue Services are aware of their duties under Disability Discrimination Legislation and will, whenever and wherever reasonable, try to provide facilities for individuals whose first language is not English, or who have other difficulties in communicating.

Every mother must:

1. Be provided with accurate educational materials, which are written in terms which can be understood by members of the general public.
2. Complete a health and medical history questionnaire and undergo a personal interview performed by a healthcare professional.
3. Provide written informed consent to proceed with the donation process which must be countersigned by the qualified healthcare professional responsible for obtaining the health history.

A healthcare professional may assist a mother in the completion of the health and medical history questionnaire and in understanding the consent statement and any other information provided by the Tissue Service. To facilitate comprehension, it is permissible to use alternative formats (e.g. audio, Braille, computer or alternative

language) for the information leaflets, the health and medical history questionnaire and consent statements. The mother must be able to clearly demonstrate they have understood this material. At present, there is no standardised way of assessing comprehension so this will be a personal judgement made by the healthcare professional.

Use of third party interpreters:

It is permissible for any third party to act as an enabler by helping to reassure the mother and to assist in establishing effective communication between the mother and the healthcare professional. The third party must not however be present during any exchange of confidential information, unless they are not personally known to the mother and understand the requirements of that part of the Human Tissue Act relevant to the donation process. Confidential parts of the process include the evaluation of the health and medical history questionnaire, the medical interview and the obtaining of valid consent. Any third party, with the permission of the mother, may accompany the mother through other parts of the donation process that do not include the exchange of confidential information.

Rationale:

There is concern that the use of third parties during any exchange of confidential information between the mother and the healthcare professional may compromise the confidentiality of the mother and the safety of any donated material. Interpreters are often part of a close community, or a family member, and this may inhibit or embarrass the mother in any confidential exchange of information. This may result in the non-disclosure of sensitive information that could affect the individual's eligibility to donate. If a third party is not fully aware of the relevant aspects of the Human Tissue Act this may make the interpretation of information incomplete and potentially put both the mother and the donated material at risk. There is also a requirement to communicate the results of any testing performed by the Tissue Services that may be of relevance to the mother or her baby's health in a way that protects their confidentiality. The continuing availability of an independent interpreter, to maintain confidentiality, should be taken into account when deciding if an individual mother may be accepted.

*Reason for change: This is a revised entry to clarify the use of interpreters by the Blood & Tissue Services.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Disease of unknown aetiology

Cord Blood

Essential information

Obligatory	See: is there is a specific entry for the disease? Must not donate.
Discretionary	If safety and quality of the donation is unlikely to be affected, discuss with Designated Clinical Support Officer. See Additional information below.

Supporting information

Additional information	When the cause of an illness is not clear, there is an unknown risk to any recipient of donated material. In certain circumstances, the aetiology could be multi-factorial, although it is not clearly established, there are no concerns relating to person to person transmission. In these cases, cells could be accepted for clinical use, based on current available evidence, after taking into consideration the impact of the donation on the donor's health.
Regulatory information	This advice is a requirement of the EU Tissue and Cells Directive.

*Reason for change: To clarify that if the safety and quality of the tissues and cells is not impacted, donation can be permitted.
Version details: CB-DSG Edition 203 Release 43 (16 March 2022)*

Diverticulosis

Cord Blood

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Infection, general](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Drug treatment

Cord Blood

Also known as: medication

Essential information

Obligatory

See: any specific [entry](#) for the disease being treated or the drug taken.

The taking of some drugs may make a mother ineligible. This could be due to the underlying disease or to the medication.

Discretionary

Self-medication with some drugs (e.g. vitamins, aspirin, sleeping tablets) need not prevent a donation being accepted, providing the mother meets all other criteria.

Supporting information

See if relevant

- [Addiction and drug abuse](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Electrolysis

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Emphysema

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Endocarditis

Cord Blood

Essential information

Obligatory	Must not donate if: Active infection.
------------	--

Supporting information

See if relevant	Infection, general
-----------------	--

Reason for change: This new entry replaces the previous entry for 'Subacute Bacterial Endocarditis'. It recognises that the cause of endocarditis is not always bacterial and the course is not always subacute.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Endometriosis

Cord Blood

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Surgery](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Epilepsy

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Mother has taken drugs with known haematological toxicity during this pregnancy.
2. Recent onset and not fully investigated.
3. Secondary to malignancy or degenerative neurological disease.

Supporting information

See if relevant

- [Malignancy](#)
- [Neurosurgery](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Eye disease

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Active ocular inflammation.
2. History of malignancy.
3. Ocular tissue transplanted.

Discretionary

History of inflammatory eye disease:

- If transient viral conjunctivitis, which is fully resolved, accept.
- For others, seek advice from Designated Clinical Support Officer.

Supporting information

See if relevant

- [Autoimmune disease](#)
- [Central nervous system disease](#)
- [Glaucoma](#)
- [Infection, general](#)
- [Malignancy](#)
- [Ocular surgery](#)
- [Ocular tissue recipient](#)
- [Steroid therapy](#)
- [Tissue and cell allograft recipients](#)

Additional information

Inflammatory eye disease can be due to:

1. Infectious causes (e.g. toxoplasmosis, CMV, leptospirosis, tuberculosis).
2. Isolated auto immune or non-infectious (e.g. HLA-B27 associated, traumatic/sympathetic ophthalmopathy, drug induced).
3. Associated with systemic diseases (e.g. Behçet's disease, arthritis, connective tissue diseases).

*Reason for change: To add 'Discretionary' and 'Additional Information' sections.
Version details: CB-DSG Edition 203 Release 53 (29 January 2024)*

Eye drops

Cord Blood

Essential information

Obligatory

Determine what they are being used to treat.

See: is there a relevant [entry](#)?

Supporting information

See if relevant

- [Autoimmune disease](#)
- [Glaucoma](#)
- [Infection, general](#)
- [Steroid therapy](#)

Additional information

Eye drops are used to treat a wide range of conditions, some of which would prevent the person from donating. It is important to know exactly why the drops are being used.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Factor V Leiden

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Fertility

Cord Blood

Essential information

Includes	Infertility
Obligatory	Must not donate if: 1. Has ever been given human gonadotrophin of pituitary origin. 2. The donor knows that they have ever been treated with Metrodin HP®.
Discretionary	If treated exclusively with non-pituitary derived gonadotrophins, accept.

Supporting information

See if relevant	• Prion-associated diseases
Additional information	The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone [FSH] and luteinizing hormone [LH]) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given. The 12-week period is an additional safeguard to avoid taking a donation early in a pregnancy. There is no evidence that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD. Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and, following advice from the Medicines and Healthcare products Regulatory Agency, the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.

Reason for change: To update the 'additional information' section with a statement that there is no evidence that transplantation of eggs or embryos might lead to spread of vCJD.

Version details: CB-DSG Edition 203 Release 43 (16 March 2022)

Filariasis

Cord Blood

Essential information

Obligatory	Must not donate.
------------	------------------------------

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Food allergy

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Gall bladder disease

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Symptomatic.
2. Associated with an inherited haemolytic anaemia (e.g. spherocytosis).

Discretionary

1. If recovered or has asymptomatic gallstones, accept.
2. If infant shown to be unaffected by any haemolytic process, accept.

Supporting information

See if relevant

- [Haemolytic anaemia](#)
- [Infection, general](#)
- [Malignancy](#)
- [Surgery](#)

*Reason for change: A link has been added for 'Haemolytic Anaemia' and for 'Malignancy'.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Giardiasis

Cord Blood

Essential information

Discretionary Accept.

Supporting information

Additional information This is a local intestinal infection that does not affect donation.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Gilbert's syndrome

Cord Blood

Essential information

Discretionary Accept.

Supporting information

Additional information Gilbert's syndrome is an inherited defect in bilirubin metabolism. It is harmless but can cause jaundice in the mother and her baby.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Glaucoma

Cord Blood

Essential information

Obligatory	Must not donate if: Received transplant of sclera during glaucoma surgery.
------------	--

Supporting information

See if relevant	• Ocular tissue recipient • Surgery • Tissue and cell allograft recipients
-----------------	--

Additional information	If surgery was performed after 1997 and the sclera was supplied through UK Transplant, this information will be stored on the National Transplant Database.
------------------------	---

*Reason for change: A link has been added for 'Ocular Tissue Recipient'.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Glucose-6-phosphate dehydrogenase (G6PD) deficiency

Cord Blood

Essential information

Obligatory

Must not donate if:

Mother or father affected by clinically significant disease, and infant is affected.

Discretionary

1. If infant shown to be unaffected, accept.
2. If father affected and male infant, accept.
3. If infant could be affected, obtain information about clinical severity of G6PD deficiency in the parent, follow-up information on child donor and discuss with Designated Clinical Support Medical Officer.

Supporting information

Additional information

This is an X-linked red cell enzyme deficiency that is variable in its severity. A Transplant Centre may accept a donor with G6PD deficiency if the phenotype is mild.

Reason for change: To improve clarity and provide additional information.

Version details: CB-DSG Edition 203 Release 29 (24 April 2018)

Glycogen storage disease (GSD)

Cord Blood

Essential information

Obligatory  Must not donate.

Supporting information

Additional information GSD is the result of defects in the processing of glycogen synthesis or breakdown within muscles, liver, and other cell types. GSD in humans is genetic, caused by an inborn error of metabolism (genetically defective enzymes) involved in these processes. There is insufficient evidence to determine whether donations from a baby with a glycogen storage disease could present a risk to recipients.

Reason for change: This is a new entry.

Version details: CB-DSG Edition 203 Release 29 (24 April 2018)

Gout

Cord Blood

Essential information

Discretionary Even if on treatment, accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Granuloma inguinale

Cord Blood

Essential information

Obligatory	Must not donate.
------------	------------------

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Growth hormone (GH)

Cord Blood

Essential information

Obligatory	Must not donate if: Has ever received human pituitary derived growth hormone.
Discretionary	If treated exclusively with recombinant-derived growth hormone, accept. In the UK, this has been since 1987.

Supporting information

See if relevant	Prion-associated diseases
-----------------	---

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Guillain-Barré syndrome

Cord Blood

Essential information

Obligatory

Refer to a Designated Clinical Support Officer:

Must not donate if:

1. Less than 24 months from resolution.
2. There has been any recurrence of symptoms.
3. The doctor who managed the mother cannot confirm a typical monophasic Guillain-Barré syndrome that recovered completely within 12 months.

Supporting information

See if relevant

If treated with immunoglobulin or plasma exchange:

- [Transfusion](#)

Reason for change: A link has been added to 'Transfusion'.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Haematological disease

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Malignant.
2. Clonal disorder such as primary polycythaemia (rubra vera), essential thrombocythaemia or monoclonal gammopathy of unknown significance (MGUS).

Discretionary

If polycythaemia or thrombocytosis is secondary to a non-malignant/clonal condition, accept.

Supporting information

See if relevant

- [Anaemia](#)
- [Haemoglobin disorders](#)
- [Immune thrombocytopenia](#)
- [Therapeutic venesection](#)

Additional information

Clonal disorders result from the proliferation of a single cell. Because they have the potential to become malignant, they are treated in the same way as malignancy.

Reason for change: Monoclonal gammopathy of unknown significance (MGUS) has been added as an example of a clonal disorder. 'Additional Information' has been added.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Haematuria

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Due to infection.
2. Due to malignancy.

Supporting information

See if relevant

- [Kidney disease](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Haemochromatosis

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Haemoglobin disorders

Cord Blood

Essential information

Obligatory

Must not donate if:

Mother or father homozygous or heterozygous for inherited haemoglobin disorders and infant affected.

Discretionary

If the cord blood or infant/child is tested for the condition and the infant is shown to be unaffected or heterozygous (trait), accept and inform the transplant centre.

Supporting information

See if relevant

[Anaemia](#)

[Sickle cell trait](#)

[Transfusion](#)

Reason for change: Stem cells from a donor who is heterozygous for a haemoglobin disorder may be accepted for transplant after a risk assessment by the transplant centre.

Version details: CB-DSG Edition 203 Release 29 (24 April 2018)

Haemolytic anaemia

Cord Blood

Essential information

Obligatory

See: Is there an [entry](#) for the condition?

If not, refer to a Designated Clinical Support Officer.

Supporting information

See if relevant

- [Autoimmune disease](#)
- [G6PD deficiency](#)
- [Haemoglobin disorders](#)
- [Hereditary elliptocytosis](#)
- [Hereditary spherocytosis](#)
- [Pyruvate kinase deficiency](#)
- [Transfusion](#)

Reason for change: A note to Refer to a Designated Medical Officer if there is no entry for the cause of the condition has been added. Additional links have been added. To include an entry for haemolytic anaemia.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Haemorrhoids

Cord Blood

Also known as: piles

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Surgery](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Headache

Cord Blood

Scenarios

Occasional headache

Discretionary Accept.

Regular headache

Obligatory **Must not donate if:**
Not investigated.

Discretionary If investigated and diagnosis does not contraindicate donation, accept.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Heaf test

Cord Blood

Essential information

Obligatory	Must not donate until: Healing.
------------	------------------------------------

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Healthcare worker

Cord Blood

Scenarios

History of inoculation injury

Obligatory See: [Inoculation injury](#)

No inoculation history

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Henna painting

Cord Blood

Also known as: hina, mehndi

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Body piercing](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Hepatitis

Cord Blood

Essential information

Obligatory	Note: Hepatitis has a number of causes including infection and hypersensitivity to drugs. Our concern is with viral hepatitis.
Discretionary	If fully recovered from non-viral hepatitis, accept.

Supporting information

See if relevant	• Hepatitis A • Hepatitis B • Hepatitis C • Hepatitis E • Hepatitis of unknown origin
-----------------	---

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Hepatitis A

Cord Blood

Scenarios

Affected mother

Obligatory

Must not donate if:

- Less than 6 months from recovery, or
- Less than 6 months since the donor was diagnosed with hepatitis A infection following laboratory testing, if the recipient has not yet started transplant conditioning therapy. If the recipient has already started transplant conditioning therapy then the Transplant Centre must be informed immediately to allow a clinical risk assessment on the best way forward for the donor. See **Additional information** below.

Discretionary

If less than 6 months from infection, but fully recovered, documented HAV RNA negative and anti-HAV IgG positive after recovery, accept.

See if relevant

- [Travel](#)

Additional information

Hepatitis A is spread by the faecal-oral route and by sewage-contaminated food and water. It can also be spread sexually. There is no long-term infection with the virus but there are many reports of transmission by transfusion. Infection may be symptom free but can be serious and occasionally fatal. The Blood Services do not test for this infection.

Blood services may screen for hepatitis A infection using a test for hepatitis A virus RNA. Donors who are diagnosed with hepatitis A infection during pre-donation screening (i.e. before the recipient has started transplant conditioning therapy) or as part of an outbreak investigation must be deferred for 6 months, even if they do not have any symptoms of the disease. After 6 months, they may donate without further testing.

Rarely, a donor may test positive for hepatitis A infection on the day of donation, after the recipient has already started transplant conditioning therapy. The Transplant Centre must then carry out an immediate clinical risk assessment regarding the risk of using the donation. Sometimes, when no good alternative HPC donor is available in a timely manner, the risk to the recipient from using the donation may be less than a significant delay to transplant to attempt to source an alternative donor.

Current or former sexual partner of an affected individual

Obligatory

Must not donate if:

Less than 6 months from recovery of current sexual partner, or from last sexual contact if a former sexual partner.

Discretionary

If shown to be immune, accept.

Additional information

There is a risk of transmitting the infection through sexual activity. Infection may be symptom free but can be serious and occasionally fatal. The 6-month exclusion allows any infection to run its natural course and for any risk of passing the infection on through donation to have passed.

Person currently or formerly sharing a home with an affected individual

Obligatory

Must not donate if:

	Less than 6 months from recovery of the last affected person in the home, or from the last contact if no longer sharing.
Discretionary	If shown to be immune, accept.
Additional information	Because hepatitis A is spread by the faecal-oral route household contacts may easily become infected. Infection may be symptom free but can be serious and occasionally fatal. The 6-month exclusion allows any infection to run its natural course and for any risk of passing the infection on through donation to have passed.
Immunisation	
Obligatory	Known exposure: Must not donate if: Less than 6 months after vaccine or intramuscular immunoglobulin was given.
Discretionary	No known exposure: Accept.
See if relevant	• Hepatitis B • Travel
Additional information	Hepatitis A immunisation is advised before travel to parts of the world where other infections relevant to donating such as malaria are common. The donor should be asked about any relevant travel history. Hepatitis A immunisation may be combined with hepatitis B immunisation. If less than 6 months from immunisation following known exposure, the donor may be accepted following individual risk assessment if the risk of delaying transplant outweighs the risk of transmission of hepatitis A.

Reason for change: Some UK blood services have introduced universal donor testing for hepatitis A, using a test for hepatitis A virus RNA. Asymptomatic bone marrow, PBSC or lymphocyte donors may therefore rarely test positive either at pre-donation screening, or on the day of donation when pre-donation screening has been negative.

Version details: CB-DSG Edition 203 Release 56 (13 October 2025)

Hepatitis B

Cord Blood

Scenarios

Mother with current hepatitis B infection

Obligatory

Must not donate.

Additional information

Hepatitis B is a serious viral infection that can lead to chronic liver disease and liver cancer (hepatoma).

Individuals who are chronically infected are sometimes referred to as 'carriers'. They often have no, or minimal, symptoms associated with their infection.

Cases are often linked to place of birth, or mother's place of birth. The condition is very common in many parts of the world and vertical spread from mother to baby is often a major route of transmission. Hepatitis B may also be acquired by injecting drug use, sexual transmission and more rarely tattoos and piercings.

Mother with previously diagnosed (recovered) hepatitis B infection

Obligatory

Must not donate if:

Less than 12 months since diagnosis.

Discretionary

If more than 12 months since diagnosis of HBV infection, and if they have successfully cleared the infection, accept.

Refer to the Designated Clinical Support Officer if advice on interpretation of test results is required.

See if relevant

- [Tissues safety](#)

Additional information

Leaving 12 months from diagnosis before testing allows sufficient time for a donor to clear any acute infection or develop markers of a chronic infection which will be detected on screening.

If less than 12 months from diagnosis, the donor may be accepted if the risk of delaying transplant outweighs the risk of transmission of hepatitis B subject to documented individual risk assessment.

Anti-HBc is required as a mandatory test under the EU Cell and Tissue Directive for cell and tissue donations, and is therefore a regulatory requirement. If the donor is HBsAg negative and HBV DNA negative anti-HBs testing is not required. Anti-HBc must be carried out to comply with regulation and there is no requirement for anti-HBs levels. However, some international stem cell registries require anti-HBs status to determine donor suitability.

Current or former sexual partner of an infected individual

Obligatory

Obtain history (including time since last sexual contact, and the dates that HBV immunisation given).

Must not donate if:

Less than 3 months from last sexual contact.

Discretionary

If more than 3 months since last sexual contact, accept.

If less than 3 months since last sexual contact, and the donor is shown to be

naturally immune, accept.

Additional information

A donor with a period of less than 3 months since the last sexual contact with an infected individual may be accepted following individual risk assessment if risk of delaying transplant outweighs the risk of transmission of hepatitis B. A shortened time between last sexual contact and testing increases the risk of not detecting a recently acquired infection on screening.

The current partner of an individual with hepatitis B infection should have been offered immunisation. If the relationship started after the diagnosis of hepatitis B, immunisation may not have been carried out.

Current or former sexual partner of person who had recovered from hepatitis B infection at the time of last sexual contact

Obligatory

Obtain history (including time since last contact, date that the partner was diagnosed with HBV infection and the date that HBV immunisation of the donor commenced).

Must not donate if:

Less than 3 months from last sexual contact with a partner who has been diagnosed with HBV infection less than 12 months ago.

Discretionary

1. If more than 3 months since last sexual contact, regardless of when the partner was diagnosed with the HBV infection, accept.
or
2. If partner was diagnosed with HBV infection more than 12 months ago and has cleared the infection at the time of last sexual contact, accept.

Additional information

A donor who had sexual contact less than 3 months ago with a partner who had been diagnosed with the HBV infection less than 12 months ago at the time of sexual contact, may be accepted following individual risk assessment if risk of delaying transplant outweighs the risk of transmission of hepatitis B.

The current partner of an individual with hepatitis B infection should have been offered immunisation. If the relationship started after the diagnosis of hepatitis B, immunisation may not have been carried out.

Person sharing a home with a person with hepatitis B infection

Obligatory

Obtain history to determine if they are still sharing a home, and if not, the time since sharing ceased

Must not donate if:

Less than 3 months since sharing ceased.

Discretionary

If more than 3 months since sharing ceased, accept.

If less than 3 months since sharing ceased, and the donor is shown to be naturally immune, accept

See if relevant

- **Immunisation** below

Additional information

A person sharing a home with a person infected with hepatitis B within the past 3 months may be accepted following individual risk assessment if the risk of delaying transplant outweighs the risk of transmission of hepatitis B.

Immunisation

Obligatory	1. If immunised following known exposure: Must not donate. 2. If immunised with no known exposure: Must not donate if: Less than 7 days after the last immunisation was given.
Discretionary	1. If immunised following known exposure: If more than 3 months from immunisation, accept. 2. If immunised with no known exposure: If more than 7 days after the last immunisation was given, accept.
See if relevant	• Hepatitis A
Additional information	Immunisation post exposure may be with specific anti-HB immunoglobulin as well as with HBsAg. Generally, immunoglobulin would only be given after a known exposure to hepatitis B. There is no requirement to monitor the anti-HBs level. May be combined with hepatitis A immunisation. Sensitive assays for HBsAg may be positive following recent immunisation. This is why a 7-day deferral is required.

Reason for change: This entry has been modified in line with the recommendations of the SaBTO Donor Selection Criteria Review Report published on 23rd July 2017.

Version details: CB-DSG Edition 203 Release 27 (27 November 2017)

Hepatitis C

Cord Blood

Scenarios

Affected mother

Obligatory

Must not donate.

Discretionary

If the individual has been told that they are HCV antibody negative, then samples should be taken to determine eligibility.

See if relevant

- [Tissues safety](#)

Additional information

Hepatitis C is a serious viral infection that can lead to chronic liver disease, liver cancer (hepatoma) and chronic fatigue syndrome. It has also been linked with malignant lymphomas and autoimmune disease. The infection is very easily spread by transfusion.

Individuals who are chronically infected are sometimes referred to as 'carriers'. They often have no, or minimal, symptoms associated with their infection.

Many cases are linked to previous drug use and, before the introduction of HCV screening of blood donations, to transfusion.

Individuals who have had Hepatitis C infection in the past, and have been told that they have been successfully treated, will usually remain HCV antibody positive for many years. As a negative HCV antibody screening test is required before their donation can be issued, their tissues/cells cannot be used.

Current or former sexual partner of an affected individual

Obligatory

Must not donate if:

Less than 3 months from the last sexual contact.

Discretionary

1. If less than 3 months from the last sexual contact and the donor/donor family reports that their current or former HCV positive partner has been successfully treated for hepatitis C infection and has been free of therapy for at least 6 months prior to the last sexual contact and continues in sustained remission, accept.
2. If more than 3 months since last sexual contact, accept.

See if relevant

- [Tissues safety](#)

Additional information

Confirmation of the success of treatment of the HCV positive partner is not required

Individuals who remain HCV RNA negative six months after completing treatment are likely to have been 'cured', with a risk of relapse of less than 1%.

In the UK, sexual transmission of HCV from an infected individual to a sexual partner is low, but not zero.

As the treated individual would have a very low (<1%) risk of relapse of infection and sexual transmission of the hepatitis C virus is rare, the transmission of hepatitis C from a successfully treated individual to a sexual partner is most unlikely. This guidance presumes that a validated NAT test for HCV is negative; if this test is stopped for any reason, the guidance will change.

Person currently or formerly sharing a home with an affected individual

Discretionary	Accept.
See if relevant	• Current or former sexual partner of an affected individual above
Additional information	Hepatitis C is neither contagious nor spread by the faecal-oral route. It is usually only spread through a direct blood to blood route. For these reasons, household contacts do not need to be deferred.

*Reason for change: To include guidance for persons with treated and successfully cleared past Hepatitis C infection.
Version details: CB-DSG Edition 203 Release 31*

Hepatitis E

Cord Blood

Supporting information

Additional information Hepatitis E is an infectious hepatitis that is usually spread through contaminated food or water. Infection may be associated with travel to countries with poor hygiene/sewage conditions but increasingly, cases of hepatitis E are being identified in the UK usually due to consumption of undercooked contaminated meat. Hepatitis E can affect non-human animals and has been found in pigs in the UK. There have been reports of transmission by transfusion and transplant. Infection in healthy individuals is often symptom free but in people with underlying problems in their immune systems, it can be serious and occasionally fatal. The UK Blood and Tissue Services currently test for this infection.

Scenarios

Affected mother

Obligatory	Must not donate if: Less than 6 months from recovery.
Discretionary	If less than 6 months from recovery and HEV RNA negative and anti-HEV IgG positive, accept.
See if relevant	• Travel

Reason for change: The obligatory deferral has been reduced from 12 to 6 months and a discretion to accept on full recovery added. Additional Information has been updated. The deferral for household and sexual contacts has been removed.
Version details: CB-DSG Edition 203 Release 29 (24 April 2024)

Hepatitis of unknown origin

Cord Blood

Scenarios

Affected mother

Obligatory

Must not donate if:

Less than 24 months from recovery.

Discretionary

1. If more than 12 months, but less than 24 months from recovery, obtain history and blood samples and refer to a Designated Clinical Support Officer.
2. If more than 24 months from recovery, accept.

Additional information

If more than 12 months and less than 24 months from recovery:

1. If negative for all markers of hepatitis B, accept.
2. If HB core antibody is positive and HBsAg is negative and HBV DNA is negative, accept.

Sexual partner of an affected individual

Obligatory

Must not donate if:

Less than 12 months from recovery of partner.

Person sharing a home with an affected individual

Obligatory

Must not donate if:

Less than 12 months from recovery of the last affected person in the home.

See if relevant

- **Sexual partner of and affected individual** above

Additional information

Most hepatitis of unknown origin will have been due to hepatitis A or hepatitis E (or non-viral causes). Additional testing for those who give a history of hepatitis between 12 and 24 months before donation will exclude the rare case of HBV which may have delayed clearance of infection and therefore will still present a risk through donation.

Reason for change: Clarification regarding hepatitis B markers has been added to the additional information. To remove the requirement for anti-HBs levels to be >100 iu/l for acceptance of stem cell donations from donors who are anti-HBc-positive provided the HBV DNA result is negative.

Version details: CB-DSG Edition 203 Release 16 (31 March 2014)

Hereditary elliptocytosis

Cord Blood

Essential information

Obligatory

1. **Must not donate if:**
Either parent has significant haemolysis.
2. **Inform Transplant Centre if:**
Cells are from an infant with/or at risk of hereditary elliptocytosis.

Discretionary

Even if a parent has significant haemolysis, if the cord blood is tested for the condition and the infant is shown to be unaffected, accept.

Supporting information

Additional information

Hereditary elliptocytosis is a variably inherited but usually dominant condition. Suitability as a donor should be discussed with a Designated Clinical Support Officer.

*Reason for change: This entry replaces the previous entry for 'Elliptocytosis'.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Hereditary spherocytosis

Cord Blood

Essential information

Obligatory

- 1. Must not donate if:**
Either parent has significant haemolysis.
- 2. Inform Transplant Centre if:**
Cells are from an infant with/or at risk of hereditary spherocytosis.

Discretionary

Even if a parent has significant haemolysis, if the cord blood is tested for the condition and the infant is shown to be unaffected, accept.

Supporting information

Additional information

Hereditary spherocytosis is a variably inherited but usually dominant condition. Suitability as a donor should be discussed with a Designated Clinical Support Officer.

*Reason for change: The entry has been brought into line with the guideline for 'Hereditary Elliptocytosis'.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Herpes simplex

Cord Blood

Supporting information

- See if relevant
- [Herpes, genital](#)
 - [Herpes, oral](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Herpes zoster

Cord Blood

Supporting information

See if relevant

- [Infection, acute](#)
- [Infectious diseases, contact with](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Herpes, genital

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Fresh lesions.
2. Primary infection occurred during this pregnancy.

Discretionary

If lesions are healing, provided there is no history of other sexually transmitted diseases, accept.

Supporting information

See if relevant

- [Sexually transmitted disease](#)

Additional information

There is no need to defer donors who have a sexual partner with herpes if the donor themselves is asymptomatic.

*Reason for change: Addition of 'Additional Information' section, to include clarification regarding sexual partners.
Version details: CB-DSG Edition 203 Release 51 (15 November 2023)*

Herpes, oral

Cord Blood

Essential information

Obligatory	Must not donate if: 1. Fresh lesions. 2. Primary infection occurred during this pregnancy.
Discretionary	If lesions are healing, accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Hormone replacement therapy (HRT)

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Used for malignancy.
2. A recipient of human gonadotrophin of pituitary origin.
3. A recipient of human pituitary growth hormone.

Discretionary

1. If treated with gonadotrophins that were exclusively non-pituitary derived, accept.
2. If treated with growth hormone that was exclusively recombinant, accept.

Supporting information

See if relevant

- [Prion-associated diseases](#)
- [Thyroid disease](#)

*Reason for change: The discretionary entry has been re-worded for clarity.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Human immunodeficiency virus (HIV)

Cord Blood

Essential information

Includes Acquired immunodeficiency syndrome (AIDS)

Scenarios

Affected mother

Obligatory Must not donate.

See if relevant • [Tissues safety](#)

Current or former sexual partner of an affected individual

Obligatory Must not donate if:
Less than 3 months from last sexual contact.

See if relevant • [Tissues safety](#)

Additional information

HIV infection can be spread through sexual activity, including oral and anal sex. Despite regular sexual contact, transmission of infection may not happen. It may however not be transmitted for a long time into a relationship. This could be because the infection becomes more active in the infected partner, the uninfected partner acquires another infection or injury to a mucous membrane, or there is a change in the use of, or failure of, barrier contraceptives (condoms etc.). In the early stages of infection, the testing used by the Blood Services may not detect the virus allowing it to be passed on by transfusion or transplantation.

Waiting 3 months from the last sexual contact will ensure that any infection is picked up by the tests used by the Blood Services. This guidance presumes that a validated NAT test for HIV is negative; if this test is stopped for any reason, the guidance will change.

Person currently or formerly sharing a home with an affected individual

Discretionary Accept.

See if relevant • **Current or former sexual partner of an affected individual above**

Additional information

HIV is neither contagious nor spread by the faecal-oral route. It is usually only spread through a direct blood to blood or sexual route. For these reasons, household contacts do not need to be deferred.

Reason for change: This entry was updated in line with the recommendations of the SaBTO Donor Selection Criteria Review Report published on 23rd July 2017. The current and former sexual partner entries have been combined. Additional information section added.

Version details: CB-DSG Edition 203 Release 27 (27 November 2017)

Human T-cell lymphotropic virus (HTLV)

Cord Blood

Scenarios

Affected mother

Obligatory | Must not donate.

See if relevant | • [Tissues safety](#)

Current or former sexual partner of an affected individual

Obligatory | Must not donate if:
Less than 3 months from last sexual contact.

See if relevant | • [Tissues safety](#)

Additional information | There is no defined infectious window period for HTLV. The risk of missing recent infection with individual sample testing is low after 3 months.

Person currently or formerly sharing a home with an affected individual

Discretionary | Accept.

See if relevant | • **Current or former sexual partner of an affected individual** above

Additional information | HTLV is neither contagious nor spread by the faecal-oral route. It is usually only spread through a direct blood to blood or sexual route. For these reasons, household contacts do not need to be deferred.

Reason for change: Entry carried over from previous Edition.

Huntington's disease

Cord Blood

Also known as: Huntington's chorea

Essential information

Obligatory	If the diagnosis is uncertain: Refer to a Designated Clinical Support Officer.
Discretionary	If diagnosis can be confirmed, accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Hydatid disease

Cord Blood

Essential information

Obligatory	Must not donate.
------------	------------------

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Hydrocephalus

Cord Blood

Essential information

Obligatory	Must not donate if: Has an indwelling shunt.
------------	---

Supporting information

See if relevant	• Neurosurgery • Spina bifida
-----------------	---

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Hypnotics

Cord Blood

Also known as: sedatives

Essential information

Includes	Sleeping tablets
Discretionary	Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Ileostomy

Cord Blood

Essential information

Obligatory	Must not donate if: 1. For malignancy. 2. Inflammatory bowel disease.
Discretionary	If the reason for the ileostomy is not of itself a reason to exclude and the stoma is healthy, accept.

Supporting information

See if relevant	• Surgery
-----------------	---

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Immune thrombocytopenia

Cord Blood

Essential information

Obligatory

Must not donate if:

Mother received treatment for the condition in the 12 months before this pregnancy.

Supporting information

See if relevant

If treated with immunoglobulin or plasma exchange:

- [Transfusion](#)

If treated with immunosuppressive therapy:

- [Immunosuppression](#)

Reason for change: The links have been revised. There is no evidence that this condition can be transmitted through cord blood or amniotic membrane.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Immunisation

Cord Blood

Scenarios

Non-exposed

Obligatory

See:

- [Immunisation, live](#)
- [Immunisation, non-live](#)

If you do not know if an immunisation is live or not, see the specific [entry](#) for the type of immunisation or refer to a Designated Clinical Support Officer.

Post exposure

Obligatory

1. **BCG:** see [BCG](#)
2. **Hepatitis A:** see [Hepatitis A](#)
3. **Hepatitis B:** see [Hepatitis B](#)
4. **Rabies:** see [Rabies](#)
5. **Smallpox:** see [Smallpox immunisation](#)
6. **Tetanus:** see [Tetanus immunisation](#)

*Reason for change: Update the 'Hepatitis A' part of the 'Post-exposure' section to refer directly to the 'Hepatitis A' entry.
Version details: CB-DSG Edition 203 Release 41 (04 August 2021)*

Immunisation, live

Cord Blood

Essential information

Discretionary	No exposure: Must not donate if: Immunised during this pregnancy.
---------------	---

Supporting information

See if relevant	• BCG • Smallpox immunisation
Additional information	Live immunisations use living viruses or living bacteria that will stimulate the immune system but do not normally cause a severe illness. They may, however, cause severe illness in people who are already unwell and have a weakened immune system.
Regulatory information	This advice is a requirement of the EU Tissue and Cells Directive.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Immunisation, non-live

Cord Blood

Essential information

Excludes	Post-exposure. See Immunisation .
Obligatory	No exposure: Hepatitis B: Must not donate if: Less than 7 days after administration
Discretionary	Other non-live immunisations, accept.

Supporting information

Additional information	Sensitive assays for HBsAg may be positive following recent immunisation. Full screening for Hepatitis B may be required. Note, hepatitis A immunisation may be combined with hepatitis B immunisation. Non-live immunisations do not use material that can cause infection. This means there is no risk to people receiving donated material from a recently immunised non-exposed donor.
------------------------	---

Reason for change: To remove Coronavirus Vaccination from obligatory section, and additional information section updated.
Version details: CB-DSG Edition 203 Release 54 (18 April 2024)

Immunoglobulin therapy

Cord Blood

Essential information

Obligatory	Must not donate if: Immunosuppressed. Mothers with recovered immunodeficiency: Refer to a Designated Clinical Support Officer.
Discretionary	1. If the intravenous or subcutaneous human immunoglobulin was given before 1980, accept. 2. Routine ante- and post-natal use of anti-D immunoglobulin, accept. 3. If single dose prophylactic immunoglobulin has been given, accept.

Supporting information

See if relevant	• Hepatitis A • Hepatitis B • Rabies • Tetanus immunisation If treated with intravenous or subcutaneous human immunoglobulin: • Transfusion
Additional information	Immunoglobulin used before 1980 is unlikely to be affected by vCJD. Single dose immunoglobulin is unlikely to pose a significant risk for transmitting vCJD.
Regulatory information	This advice reflects advice from the MSBTO committee of the Department of Health.

Reason for change: A link to 'Transfusion' has been added.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Immunosuppression

Cord Blood

Essential information

Obligatory

Must not donate if:

Immunosuppressed.

Mothers with recovered immunodeficiency:

Refer to a Designated Clinical Support Officer.

Supporting information

See if relevant

- [Autoimmune disease](#)
- [Immunoglobulin therapy](#)
- [Steroid therapy](#)

Regulatory information

This advice is a requirement of the EU Tissue and Cells Directive.

Reason for change: Additional links have been added.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Infection, acute

Cord Blood

Essential information

Obligatory

See: is there is a specific [entry](#) for the disease you are concerned about?

Must not donate if:

1. Evidence of active infection.
2. Less than 2 weeks from recovery.
3. Less than 7 days from completing systemic antibiotic, antifungal or antiviral treatment.

Discretionary

Common viral respiratory tract infections such as colds, sore throats and seasonal influenza, if recovering, accept. See **Additional information** below.

Cold sores, genital herpes, accept.

Supporting information

See if relevant

- [Coronavirus infection](#)
- [Herpes, genital](#)
- [Herpes, oral](#)
- [MRSA](#)
- [Myocarditis](#)
- [Steroid therapy](#)
- [Viral haemorrhagic fever](#)
- [West Nile Virus](#)

Additional information

Many infections can be spread by donated material. It is important that the mother does not pose a risk of giving an infection to a recipient. Waiting 2 weeks from when the infection is resolved and seven days from completing systemic antibiotic, antifungal or antiviral treatment makes it much less likely that there will still be a risk of the infection being passed on.

There is no evidence that cold sores, genital herpes and common upper respiratory infections such as colds and sore throats can be passed on by donated material but it is still necessary to wait until any such infection is obviously getting better before allowing anyone to donate.

Three distinct types of influenza infection need to be considered separately: seasonal influenza, pandemic influenza and avian influenza. This guidance applies only to seasonal influenza; avian and pandemic influenza are out with the scope of this guidance. Donors with these diagnoses should not be accepted. Any outbreaks of avian or pandemic influenza will be communicated via public health alert guidance for professionals.

Seasonal influenza in the UK normally extends over a period of approximately 16 weeks during the winter months. Due to the spectrum of disease presentation, only the minority of infected individuals are tested for respiratory viruses and during the annual epidemics, most cases are diagnosed clinically. Systemic infection with viraemia is not a feature of seasonal influenza.

Unusual bacterial/fungal/protozoal infections:

Specialist microbiological advice should be sought when considering using cells and tissues from donors who have had unusual infections in the past, including those acquired outside of Western Europe. This should include infections common in immunocompromised patients, or infections which lie dormant or may be difficult to eradicate.

Regulatory information Part of this advice is a requirement of the EU Tissue and Cells Directive.

*Reason for change: Updated guidance regarding donors who are recovering from seasonal influenza.
Version details: CB-DSG Edition 203 Release 37 (15 July 2020)*

Infection, chronic

Cord Blood

Essential information

Obligatory

Must not donate.

Discretionary

1. Acne:

Most donors with acne can be accepted.

2. Chronic fungal infections:

- a. If on local therapy for superficial infections only, accept.
- b. If on systemic antifungal treatment only for treatment of a localised, non-systemic fungal infection, and there are no complications, accept.
- c. If otherwise more than 7 days from completing systemic antifungal therapy, accept.

3. Typhoid and paratyphoid:

If more than 7 days from completion of antibiotic course and last symptoms, accept.

Supporting information

See if relevant

- [Steroid therapy](#)

Additional information

Typhoid and paratyphoid are gastrointestinal infections which rarely have a chronic carrier state. It is usually caught while travelling. It is passed by the faecal-oral route and is not transmitted by tissue or cell transplantation.

Unusual bacterial/fungal/protozoal infections:

Specialist microbiological advice should be sought when considering using cells and tissues from donors who have had unusual infections in the past, including those acquired outside of Western Europe. This should include infections common in immunocompromised patients, or infections which lie dormant or may be difficult to eradicate.

Local fungal infections (e.g. nail infection or athlete's foot):

Systemic oral antifungal treatment may be prescribed to treat localised fungal nail infections or athlete's foot which are difficult to eradicate. Despite the systemic treatment, due to the fact that the infection is localised to the nails/digits, the risk to donated tissue/cells is considered to be remote.

Regulatory information

Part of this advice is a requirement of the EU Tissue and Cells Directive.

Reason for change: To add guidance for acceptance of donors on oral antifungal treatment for localised nail infections or athlete's foot.

Version details: CB-DSG Edition 203 Release 38 (07 October 2020)

Infection, general

Cord Blood

Essential information

Obligatory

See: is there a specific [entry](#) for the disease?

Supporting information

See if relevant

Decide if the infection is of short duration with no long lasting carrier stage (e.g. flu):

- [Infection, acute](#)

Or if lasting a long time (more than a few weeks) and possibly with long lasting carriage of the infecting organism (e.g. malaria or typhoid):

- [Infection, chronic](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Infection, tropical

Cord Blood

Essential information

Obligatory

Must not donate if:

Filariasis or leishmaniasis.

Supporting information

See if relevant

- [Congo fever](#)
- [Malaria](#)
- [South American trypanosomiasis, risk of](#)
- [Viral haemorrhagic fever](#)

Other infections, see:

- [Infection, general](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Infectious diseases, contact with

Cord Blood

Essential information

Obligatory

See: is there a specific [entry](#) for the disease with which there has been contact?

Must not donate if:

Within the incubation period for the condition or, if this is not known, less than 4 weeks from last contact.

Discretionary

1. If the infection is known to lead to permanent immunity (e.g. chickenpox, measles, mumps, rubella, whooping cough) and there is a definite history of past infection with the disease with which contact has occurred, accept.
2. Contact with common upper respiratory tract infections (e.g. colds, sore throats, influenza, SARS-CoV-2), accept.
3. Contact with norovirus and other causes of diarrhoea and vomiting, provided the donor is symptom free, accept.
4. Contact with skin conditions which are not transmissible by donated material (such as scabies, ringworm, tinea) if no signs of infection, accept.
5. Individuals who have been prescribed prophylactic antibiotics after contact with meningitis, anthrax or chlamydia, provided they are symptom free, accept.

Supporting information

See if relevant

- [Coronavirus infection](#)
- [Hepatitis](#)
- [Hepatitis A](#)
- [Hepatitis B](#)
- [Hepatitis C](#)
- [Hepatitis E](#)
- [HIV](#)
- [HTLV](#)
- [Meningitis](#)
- [Mpox](#)
- [Sexually transmitted disease](#)
- [Smallpox immunisation](#)
- [Syphilis](#)
- [Tuberculosis](#)

Additional information

Many infectious diseases can be passed on through donated material, even before a potential donor develops any symptoms of the infection. This may lead to serious infection in the person receiving a donation.

Many diseases are not infectious and so are not normally a risk.

Contacts with meningitis or anthrax are often prescribed prophylactic antibiotics. These should prevent the disease from developing, so provided the potential donor is well, they may be accepted.

If in doubt, contact a Designated Clinical Support Officer.

Reason for change: To add 'discretionary' and 'additional information' sections and to update the 'see if relevant' section with

additional links.

Version details: CB-DSG Edition 203 Release 48 (13 December 2022)

Inflammatory bowel disease (IBD)

Cord Blood

Essential information

Includes	Crohn's disease, ulcerative colitis.
Obligatory	Must not donate.
Discretionary	Accept if mother well and in stable remission off treatment. Inform transplant centre there is a history of autoimmune disease in a first-degree relative.

Supporting information

See if relevant	• Infection, general • Malignancy • Radiation therapy
-----------------	---

Additional information	The cause of these conditions is not fully understood and may include infection. Lesions caused by the disease can increase the risk of bacteria entering the blood stream.
------------------------	---

*Reason for change: 'See if Relevant' section has been added.
Version details: CB-DSG Edition 203 Release 41 (01 August 2021)*

Inherited diseases

Cord Blood

Essential information

Obligatory

See: is there a specific [entry](#) for the condition?
If not, refer to a Designated Clinical Support Officer.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Inoculation injury

Cord Blood

Essential information

Definition/s	An inoculation injury is a non-consented injury or assault in which an individual is exposed to potentially infective material that could be transferred through donation. The causes may range from a sharps injury to bites, punches and abrasions, or sexual assault where mucous membranes have been contaminated with human blood or other body fluids. It also applies to any inoculation injury with abnormal prions from any species.
Includes	Human bite.
Obligatory	Must not donate if: 1. The incident involved any material containing abnormal prions. 2. Less than 3 months after the date of an inoculation injury, or contamination of mucosa or non-intact skin with blood or body fluids. 3. Under ongoing investigations following exposure, refer to Designated Clinical Support Officer.

Supporting information

See if relevant	• Animal bite, non-human • Hepatitis • HIV • HTLV • Prion-associated diseases • Tissues safety • Xenotransplantation
Additional information	Human blood or body fluids may be contaminated with infective material such that the infection may then be passed on by donated material. Waiting 3 months (if validated tests for infectious markers that include HBV, HCV HIV NAT are negative) helps to ensure that any infection is not passed on. Donors who are under investigation may be accepted subject to individual risk assessment.

Reason for change: The 'Definitions' section was updated as part of the implementation of recommendations from the FAIR III report. Additional 'see if relevant' links added. 'Additional information' section updated.
Version details: CB-DSG Edition 203 Release 51 (15 November 2023)

Irritable bowel syndrome (IBS)

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Jaundice

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Jaundiced or has a history of jaundice.
2. If the cause of the jaundice was viral see the specific [entry](#) for that condition.
3. If the cause of the jaundice was not known, treat as [Hepatitis of unknown origin](#).

Discretionary

1. If fully recovered from a non-viral cause of jaundice (this includes, but is not limited to, physiological jaundice of the newborn, gall stones and drug reactions), accept.
2. If due to Gilbert's syndrome, accept.

Supporting information

See if relevant

- [Gall bladder disease](#)
- [Gilbert's syndrome](#)
- [Hepatitis A](#)
- [Hepatitis B](#)
- [Hepatitis C](#)
- [Hepatitis E](#)
- [Hepatitis of unknown origin](#)

Additional information

Many things can cause jaundice. The concern is with infectious causes that might be passed on by donation.

Reason for change: In 'Obligatory' the link to Hepatitis B' has been changed to 'Hepatitis of Unknown Origin'. There have been other minor changes to improve clarity and to avoid the unnecessary exclusion of donors.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Kidney disease

Cord Blood

Scenarios

Acute nephritis

Obligatory

Must not donate if:

Less than 12 months since recovery.

Discretionary

All tissues:

1. Self-limiting renal disease (e.g. single attacks of glomerulonephritis, pyelitis) from which recovery has been complete, do not necessarily disqualify the donor.
2. If there is doubt about the diagnosis, refer to a Designated Clinical Support Officer.

Additional information

If the donor is well and has not received treatment to suppress the condition in the last 12 months, it is unlikely that their donation will pose a risk to the recipient.

Chronic nephritis

Obligatory

Must not donate.

Reason for change: To align the guidance with that for blood donors, the deferral period following an attack of 'Acute Nephritis' has been reduced from five years to 12 months

Version details: CB-DSG Edition 203 Release 16 (31 March 2014)

Laser treatment

Cord Blood

Essential information

Obligatory

Must not donate if:

For malignancy.

Discretionary

1. If for basal cell carcinoma, treatment is completed and fully recovered, accept.
2. If for cervical carcinoma in situ, see [Cervical dysplasia](#).
3. If for cosmetic purposes, accept when healed.
4. If laser refractive surgery to the cornea, accept when healed.

Supporting information

See if relevant

- [Basal cell carcinoma](#)
- [Cervical dysplasia](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 43 (16 March 2022)

Leishmaniasis

Cord Blood

Also known as: kala-azar

Essential information

Obligatory  Must not donate.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Leukaemia

Cord Blood

Essential information

Obligatory	Must not donate.
------------	------------------------------

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Malaria

Cord Blood

Essential information

Obligatory

Must not donate if:

1. The mother has ever had malaria.
2. The mother has had an undiagnosed fever (that could have been malaria) while abroad or within 4 months of leaving a malaria endemic area.
3. The mother has lived in any malarial endemic area for a continuous period of 6 months or more at any time of life.
4. Less than 12 months after last leaving a malaria endemic area.

Discretionary

Mothers who have had malaria diagnosed in the past:

- If more than 3 years have passed since anti-malaria therapy has been completed, and symptoms caused by malaria have resolved, and a validated test for malaria antibody is negative, accept.
- If the donor (with a history of malaria) has revisited a malaria endemic area, and at least 4 months have passed since return, and a validated test for malaria antibody is negative, accept.

Mothers who have EVER had an undiagnosed fever that could have been malaria while in a malaria area or within 4 months of leaving a malaria endemic area:

- If at least 4 months have passed since the donor returned from the malaria endemic area, or from the date of recovery from symptoms (undiagnosed fever) that may have been caused by malaria, whichever is later, and a validated test for malaria antibody is negative, accept.

Mothers who have EVER been resident in a malaria endemic area for 6 months or more:

- If at least 4 months have passed since the date of the last potential exposure to malaria, and a validated test for malaria antibody is negative, accept.

For all other mothers:

- If at least 4 months and less than 12 months have passed since return from a malaria endemic area, and a validated test for malaria antibody is negative, accept.
- If travel to a malaria endemic area is more than 12 months prior to donation, and the mother has never been diagnosed with malaria, has never had an undiagnosed fever while abroad or within 4 months of leaving a malaria endemic area, and has not lived in a malaria endemic area for a continuous period of 6 months or more at any time of life, the mother can be accepted without the need for malaria antibody testing.

For all of the above:

- If malaria antibody testing is indicated as outlined above and the result is inconclusive or positive, obtain details of exposure and treatment and discuss

with the Designated Clinical Support Officer.

- If the malaria antibody test is positive or inconclusive, additional nucleic acid testing (NAT) for malaria on a maternal and a cord blood sample may be utilised to determine the safety of the cord blood donation. In case of confirmed negative NAT results, a risk assessment must be documented and, if accepted, the details must be discussed at selection with the transplant centre.

Supporting information

See if relevant

- [Geographical Disease Risk Index](#) for countries with a current endemic malaria risk

Additional information

Cases of malaria transmission have occurred many years after the mother was last at risk of becoming infected with malaria. This is mainly a problem in people who have had repeated episodes of infection with malaria. This is uncommon, but before allowing someone who has had, or may have had malaria to give a donation, it is safer to test for malaria antibodies rather than to wait a specific length of time. Malaria may be fatal.

Some countries have malaria as well as tropical viral risk. Both risks have to be considered if the mother had symptoms after travel or stay.

*Reason for change: The 'Discretionary' entry has been expanded to include information on the option for NAT testing if required.
Version details: CB-DSG Edition 203 Release 46 (31 May 2022)*

Malaria - contact in the UK

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Malignancy

Cord Blood

Essential information

Obligatory

Must not donate.

Discretionary

1. If this was a basal cell carcinoma (rodent ulcer) and treatment is completed and all wounds are healed, accept. If any systemic medical treatment was required, refer to Designated Clinical Support Officer.
2. If the potential donor has a non haematological (non-clonal) premalignant condition (e.g. polyposis coli, prostatic intraepithelial neoplasia (PIN) or Barrett's oesophagus) that is being regularly monitored, or has had a similar condition cured and has been discharged from follow-up, accept.
3. If the potential donor has been cured of a carcinoma in situ (CIS) and discharged from follow-up, accept. Donors who have been returned to routine screening following treatment for cervical CIS can be accepted. Examples of CIS include cervical or vulval CIS, ductal CIS of the breast (DCIS) and Bowen's disease.
4. If the potential donor has had a diagnosis of melanoma in situ (including lentigo maligna), refer to Designated Clinical Support Officer to confirm they have not had an invasive melanoma (e.g. lentigo maligna melanoma).
5. Potential donors with a high risk of cancer due to family history or following genetic tests, even if had or having prophylactic surgery or on prophylactic medication (e.g. Tamoxifen), or on routine follow-up, accept.

Supporting information

See if relevant

- [Basal cell carcinoma](#)
- [Cervical dysplasia](#)
- [Surgery](#)
- [Transfusion](#)

Additional information

Many malignancies spread through the blood stream and by invading surrounding tissues. Viruses that can be spread by blood and tissue donation can also cause some malignancies. For these reasons, it is considered safer not to accept blood from people who have had a malignancy.

Basal cell carcinoma (rodent ulcer) does not spread through the blood, therefore people who have had successful treatment may donate.

The term carcinoma in situ (CIS) refers to a group of abnormal cells which have not invaded deeper tissue or spread to another part of the body. Donors who have been cured and discharged from follow-up may donate. For cervical CIS, donors can be accepted if treatment is complete and any follow-up smear, if performed, did not show abnormal cells. Regular screening smears are not defined as follow-up.

Premalignant conditions are very common, particularly in older donors. Regular monitoring should prevent donors with invasive malignancy from being accepted. However donors with a haematological clonal pre-malignant condition should not be accepted for tissue donation.

Melanoma in situ which has been cured by excision is not associated with a risk of metastasis. Patients with a confirmed diagnosis of melanoma in situ (i.e. Breslow thickness of 0 and no regression) do not require ongoing follow-up beyond the initial post-operative appointment.

Lentigo maligna is a form of melanoma in situ found on the head and neck. It should be distinguished from lentigo maligna melanoma which is a true malignant melanoma.

*Reason for change: Advice has been added for basal cell carcinoma treated systemically.
Version details: CB-DSG Edition 203 Release 31 (30 September 2019)*

Mantoux test

Cord Blood

Essential information

Obligatory

Must not donate unless:
Negative and no further investigations planned.

Supporting information

See if relevant

- [Tuberculosis](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Marfan syndrome

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Measles

Cord Blood

Scenarios

Affected individual

Obligatory | See: [Infection, acute](#)

Contact with an affected individual

Obligatory | See: [Infectious diseases, contact with](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Meningitis

Cord Blood

Scenarios

Affected individual

Obligatory See: [Infection, acute](#)

Contact with an affected individual

Discretionary Even if on prophylactic antibiotics, accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Mental health problems

Cord Blood

Essential information

Obligatory

Must not donate if:

Not able to fully understand and consent to the donation process and to the testing of their blood for diseases that may affect its suitability for use.

Supporting information

See if relevant

- [Communication difficulties](#)

Additional information

Many people have mental health problems that can be controlled with regular medication. Providing individuals are well on the day of donation and have the mental capacity to give full informed consent, there is no reason why they cannot donate whether on medication or not. Individuals who are over anxious, depressed, manic or psychotic cannot always give valid consent, or fully understand why they are being asked certain questions.

Reason for change: To ensure that all donors with mental health conditions can donate if they are well enough to do so and have the mental capacity to give full informed consent.

Version details: CB-DSG Edition 203 Release 16 (31 March 2014)

Methicillin resistant staphylococcus aureus (MRSA)

Cord Blood

Supporting information

See if relevant

- [Infection, general](#)

Additional information

Staphylococcus aureus is a widely occurring skin commensal organism. The carrier status or exposure of the mother is not relevant to donation.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Mitral valve prolapse

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Mosquito-borne viruses

Cord Blood

Essential information

Definition/s	Mosquito-borne virus risk areas are shown in the Geographical Disease Risk Index which includes details of the specific viral risks present. The day that a donor leaves a risk area is defined as Day 0.
Includes	• Chikungunya Virus, also known as CHIKV • Dengue Virus, also known as Dengue Fever • Yellow Fever, also known as YF • Zika Virus, also known as ZIKV, and Zika Virus Fever
Obligatory	Must not donate if: 1. A mother has been diagnosed with Chikungunya, Dengue, Yellow Fever or Zika Virus infection whilst in a mosquito-borne virus risk area or following her return to the UK during this pregnancy. 2. A mother has either had a history of symptoms suggestive of Chikungunya, Dengue, Yellow Fever or Zika Virus infection whilst in a mosquito-borne virus risk area or following her return to the UK during this pregnancy. 3. In other cases, it is 28 days or less since the mother was last in a mosquito-borne virus risk area.

Supporting information

See if relevant	• Geographical Disease Risk Index for countries with a current mosquito-borne virus risk • Infection, tropical • Malaria • South American trypanosomiasis • South American trypanosomiasis, risk of
Additional information	Should a situation arise where a risk assessment is warranted, seek expert virologist advice. Additional laboratory testing may be available and appropriate (e.g. referral to the Porton Down reference laboratory). Chikungunya, Dengue, Yellow Fever and Zika viruses are spread by the day-flying mosquito species <i>Aedes aegypti</i> and <i>Aedes albopictus</i>. These mosquitos are typically found in tropical and subtropical regions including the Caribbean, South and Central America, Mexico, Africa, the Pacific Islands, South East Asia, the Indian sub-continent, Hawaii and northern parts of Australia. The range of <i>Aedes albopictus</i> is increasing into more temperate zones, leading to outbreaks of mosquito-borne virus disease in new areas. This includes seasonal outbreaks of Dengue and Chikungunya in parts of Europe. The GDRI entry for mosquito-borne virus risk areas will indicate whether a risk should be applied all year or can be applied seasonally. Position statements on mosquito-borne viruses are available.

Chikungunya Virus:

Chikungunya is an alphavirus that can cause a wide spectrum of disease. This may range from no or minimal symptoms to death. Most commonly it causes arthritis (typically in the knee, ankle and small joints of the extremities), high fever and a maculopapular rash.

Chikungunya Virus is found in countries in Asia, Africa, Central and South America, and in the islands of the Caribbean. It is known to be spread by blood in symptomatic cases and on theoretical grounds could be spread by transfusion and transplantation of tissues and organs from people with pre-symptomatic or asymptomatic disease. A number of visitors returning from endemic areas to the UK have been diagnosed with this infection.

Dengue Virus:

Dengue Virus is a flavivirus that typically gives rise to abrupt high fever with a range of accompanying symptoms.

Dengue fever (DF) is the most common insect-borne disease worldwide. Dengue is currently considered endemic in over 140 countries.

Overall, up to 75% of cases are asymptomatic or mild. If symptoms occur, they can range from non-specific acute febrile illness to severe disease including dengue haemorrhagic fever and dengue shock syndrome. Mild cases may be misdiagnosed as other febrile illnesses.

Yellow Fever Virus:

Yellow Fever Virus is a flavivirus which is found in Africa, South America, Central America and parts of the Caribbean.

Symptoms of Yellow Fever include high temperature, headache, nausea and vomiting, muscle pains and backache. One in four individuals may suffer from jaundice and bleeding from the gastrointestinal tract and other sites.

Zika Virus:

Zika virus is a flavivirus which was known to occur in Africa and parts of Southeast Asia. More recently, Zika Virus has been associated with epidemic outbreaks in the Pacific region and in the Americas. As well as mosquito-borne infection, Zika Virus can be spread through sexual transmission.

Infection is usually asymptomatic or presents as a mild self-limiting febrile illness. More severe disease and hospitalisation are rare but infection during pregnancy carries a high risk of congenital abnormalities in the baby. Zika Virus infection may be mistaken for Chikungunya or Dengue infections as these viruses often co-circulate.

Reason for change: Entry renamed from 'Tropical viruses' to 'Mosquito-borne viruses' with equivalent changes to terminology throughout the text. Information about seasonal risk has been added to 'Additional information'.

Version details: CB-DSG Edition 203 Release 58 (11 August 2026)

Mpox

Cord Blood

Also known as: monkeypox, previously

Supporting information

Additional information Mpox was previously known as Monkeypox. In November 2022, WHO recommended mpox as the new name for Monkeypox disease. Mpox is endemic in some African countries. During 2022, a multi-country outbreak was identified with cases in the UK, Europe, North America and other regions.

The incubation period of mpox is up to 21 days. The initial symptom are fever, myalgia, fatigue and headache. These symptoms are followed by a rash starting from the site of the primary infection, this rash develops into vesicles and pustules followed by scabs. Infectivity may start during initial symptoms and lasts until the rash clears and all scabs have dropped off.

Staff should be alert for donors who report rashes and illnesses consistent with mpox, regardless of sexual behaviour, travel history or other risk factors.

Mpox does not spread easily between people. Human-to-human transmission occurs through contact with:

- infectious material from skin lesions
- respiratory droplets in prolonged face-to-face contact
- virus-contaminated objects such as bedding or clothing

During the 2022 multi-country outbreak, the predominance of cases among men who have sex with men (MSM) and the distribution of the mpox skin rash at presentation, suggests mpox transmission is associated with direct contact during sex.

Contacts may have received vaccination, to reduce the risk of serious illness. Usually vaccination will be with Imvanex® or other third generation vaccine against smallpox. Contacts are eligible to donate once they satisfy the requirements of **Contact with an affected individual** and **Immunisation for contact or risk** above.

Healthcare workers may also have received vaccination to protect against mpox in the event of possible exposure to mpox during their work. They will be working in accordance with Infection Prevention and Control policies and with suitable personal protective equipment, which if not breached means they are eligible to donate.

Other recipients of vaccination for mpox must be assessed according to **Immunisation for contact or risk** above.

Imvanex® is a live attenuated non-replicating third generation smallpox vaccination. For donor selection purposes, this can be assessed as a non-live vaccine but primarily donors must be assessed according to their individual risk of exposure to mpox. The deferral of some donors for 4 weeks from the date of a non-live vaccination allows symptoms of mpox from prior exposure to become evident (incubation period up to 21 days) and encompasses the time for maximum efficacy of the immunisation (up to 4 weeks). Donors should be deferred until completion of a course of vaccination.

Post donation illness If the donor has retrospectively reported contact with mpox within incubation period, donation could be discarded or seek public health advice to determine the risk.

Scenarios

Affected individual

Obligatory

Must not donate.

Discretionary

If the donor has recovered from confirmed or suspected mpox infection, and

- It is at least 28 days since the diagnosis of mpox was made, and
- It is at least 14 days since recovery, and the donor remains well, and
- It is at least 14 days since all skin lesions have healed, and
- It is more than 7 days since completing any antiviral or antibiotic therapy, and
- The donor has been discharged from all follow-up (including public health surveillance),

accept.

Additional information

Post donation illness:

Donors must be provided with information about contacting the tissue establishment if they develop any illness within 21 days after donation. Donation should be discarded.

Contact with an affected individual

Includes

- Individuals who have been identified by public health teams as a close contact of an individual with mpox.

Obligatory

Must not donate.

Discretionary

If it is more than 21 days since last contact, and

- The donor has no symptoms of mpox, and
- The donor has completed any isolation period, and
- The donor has been discharged from all follow-up (including surveillance by public health), and
- The donor fulfils the criteria in **Immunisation for contact or risk** below regarding vaccination, if applicable,

accept.

Additional information

Post donation illness:

If the donor has retrospectively reported contact with mpox within incubation period, donation could be discarded or seek public health advice to determine the risk.

Immunisation for contact or risk

Excludes

- Individuals who have received vaccination because they work in a health care setting – see 'Immunisation - no known contact' below.

Obligatory

Must not donate.

Discretionary

If the donor fulfils the criteria in **Contact with an affected individual** above, and:

- It is more than 4 weeks since the most recent dose of a non-live or attenuated smallpox vaccination (e.g. Imvanex®), and:

- The course of vaccination (if more than 1 dose) is complete, accept.

Immunisation - no known contact

Includes	• Individuals who have received vaccination because they work in a health care setting.
Discretionary	An individual who has received routine vaccination with Imvanex® or another third-generation smallpox vaccination in an occupational setting, can be accepted provided that they are not deemed to be at risk due to an exposure episode.
See if relevant	• Immunisation

Reason for change: The title and contents have been updated with the new name as recommended by WHO. Inclusion of sections for donors who have received vaccination either because they could be a close contact, have risk of exposure, or have received vaccination because they are health care workers. Additional Information applicable for the whole entry contained within one section.

Version details: CB-DSG Edition 203 Release 49 (12 April 2023)

Multiple sclerosis (MS)

Cord Blood

Essential information

Obligatory  Must not donate.

Supporting information

Additional information As the cause of multiple sclerosis is not certain and there is a possibility that there is an underlying infectious agent, donation is not permitted.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Mumps

Cord Blood

Scenarios

Affected individual

Obligatory

See: [Infection, acute](#)

Contact with an affected individual

Obligatory

See: [Infectious diseases, contact with](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Muscular dystrophy

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Myasthenia gravis (MG)

Cord Blood

Essential information

Obligatory	Must not donate.
------------	------------------

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Myelodysplastic syndrome (MDS)

Cord Blood

Essential information

Obligatory  Must not donate.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Myeloproliferative syndrome

Cord Blood

Essential information

Obligatory  Must not donate.

*Reason for change: This entry has been added to clarify the eligibility of donors with this condition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Myocarditis

Cord Blood

Essential information

Obligatory	Must not donate if: 1. Not recovered. 2. Occurred during this pregnancy.
------------	---

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Ménière's disease

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Neurofibromatosis (NF)

Cord Blood

Essential information

Obligatory	Must not donate if: History of malignant changes.
------------	--

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Neurosurgery

Cord Blood

Essential information

Obligatory

Must not donate.

Discretionary

1. If carried out in the UK after 1992, providing the reason for the surgery is not itself a reason for exclusion, accept.
2. If burr hole surgery only, accept.
3. If it can be shown that dura mater was not used during surgery and there is no evidence of malignancy, the mother may be accepted by a Designated Clinical Support Officer.

Supporting information

See if relevant

- [Malignancy](#)
- [Prion-associated diseases](#)
- [Surgery](#)

Regulatory information

This advice is a requirement of the EU Tissue and Cells Directive.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Night sweats

Cord Blood

Essential information

Obligatory	Must not donate if: Unexplained.
------------	-------------------------------------

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Non-specific urethritis (NSU)

Cord Blood

Scenarios

Acute NSU

Obligatory See: [Infection, acute](#)

Chronic NSU

Obligatory Must not donate.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Cord Blood

Essential information

Obligatory

Assess reason for treatment and see relevant [entry](#).

Discretionary

If medication is self-prescribed and the mother meets other criteria, accept.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Ocular surgery

Cord Blood

Supporting information

See if relevant

- [Eye disease](#)
- [Laser treatment](#)
- [Malignancy](#)
- [Ocular tissue recipient](#)
- [Tissue and cell allograft recipients](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Ocular tissue recipient

Cord Blood

Essential information

Obligatory

See: [Prion-associated diseases](#)

Must not donate if:

Has received a corneal, scleral or limbal tissue graft or limbal or corneal epithelial cells.

Supporting information

Additional information

If the surgery was performed after 1997 and the tissue was supplied through UK Transplant, this information will be stored on the National Transplant Database.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Operations

Cord Blood

Essential information

Obligatory See: [Surgery](#)

Supporting information

See if relevant • [Transfusion](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Organ donor

Cord Blood

Essential information

Obligatory	See: Surgery
Discretionary	Accept.

Supporting information

See if relevant

- [Transfusion](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Organ recipient

Cord Blood

Essential information

Obligatory	Must not donate.
Discretionary	Refer to a Designated Clinical Support Officer for individual risk assessment.

Reason for change: This is a new entry.
Version details: CB-DSG Edition 203 Release 50 (04 July 2023)

Osteoarthritis

Cord Blood

Essential information

Obligatory

Must not donate if:

It is less than 7 days from any invasive treatment or investigation, including but not limited to joint injections.

Discretionary

If the donor has been treated by joint injection, and:

1. Treatment was performed within the NHS, or treatment was performed by a Qualified Health Care Professional (as defined in the [Complementary therapy](#) entry), and
2. It is at least 7 days from any joint injection with steroid, and
3. It is at least 7 days from any joint injection with autologous platelet rich plasma (PRP), and
4. Any wound or puncture mark is fully healed without any evidence of infection, accept.

Supporting information

See if relevant

- [Complementary therapy](#) (for the approved list of Qualified Health Care Professionals)
- [Disabled mother](#)
- [Nonsteroidal anti-inflammatory drugs](#)
- [Steroid therapy](#)
- [Surgery](#)

Additional information

Donors who have severe pain or disability that makes it difficult for them to get on or off the donation couch should not donate. Nonsteroidal anti-inflammatory drugs (NSAIDs) taken for arthritis may affect platelet function. See the [Nonsteroidal anti-inflammatory drugs](#) entry if relevant.

Some individuals may undergo arthroscopy as part of the assessment and investigation of their condition; this is usually performed by a rigid endoscope.

Some individuals may receive joint injections to relieve the symptoms of osteoarthritis. These may be intra-articular (into the joint) or periarticular (around the joint). Treatments may include steroids, hyaluronic acid or platelet rich plasma (PRP). Individuals who have received joint injections must wait at least 7 days before donation to avoid potential risks of bacteraemia. If the donor is uncertain about the treatment that was given, refer to a Designated Clinical Support Officer.

The rigour of sterile precautions for any procedure involving PRP should be taken into consideration when accepting donors. Procedures carried out for osteoarthritis within the NHS by licensed UK health professionals are not likely to raise concerns regarding the rigour of sterile precautions, although the 7-day deferral should still be applied.

Reason for change: Guidance on the acceptance of donors treated with joint injection has been added. 'See if relevant' links have been added.

Version details: CB-DSG Edition 203 Release 59 (6 October 2026)

Osteomalacia

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Osteomyelitis

Cord Blood

Essential information

Obligatory

Must not donate if:

Less than 2 years from completing treatment and cure.

Supporting information

Additional information

Sometimes it is difficult to be certain that all infection has been eliminated.
Waiting 2 years minimises the risk of any infection being passed on by a donation.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Osteoporosis

Cord Blood

Supporting information

See if relevant

- [Steroid therapy](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Ovarian cyst

Cord Blood

Essential information

Obligatory	Must not donate if: Malignant.
------------	-----------------------------------

Supporting information

See if relevant	• Malignancy • Surgery
-----------------	--

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Paget's disease of bone

Cord Blood

Also known as: osteitis deformans

Essential information

Includes Osteitis deformans.

Discretionary Accept.

Supporting information

Additional information Paget's disease of bone is very common in the UK, affecting about 1 in 20 adults aged over 50 years. The cause is not known. Many people with the condition have no symptoms and so will be accepted by the blood and tissue services. There is no evidence that it is spread by donation. It is most commonly treated with painkillers and bisphosphonates. The use of these drugs is accepted for other conditions, so there seems no reason why individuals with Paget's disease of bone on treatment should not be accepted, provided that they are otherwise acceptable.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Painkillers

Cord Blood

Essential information

Obligatory

Assess reason for treatment and see relevant [entry](#).

Must not donate if:

Taken for a serious long-term illness.

Supporting information

See if relevant

- [Nonsteroidal anti-inflammatory drugs](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Parvovirus B19

Cord Blood

Essential information

Includes Human parvovirus B19, slapped cheek syndrome, erythema infectiosum, fifth disease.

Supporting information

See if relevant

- [Infectious diseases, contact with](#)

Additional information Parvovirus B19 is a viral infection which occurs most commonly in children. The virus can be transmitted through droplet spread (respiratory), or from mother to baby, or via blood transfusion. Outbreaks of parvovirus B19 occur every 3 to 4 years during the late winter and early spring period. Following exposure, the incubation period is 14 to 21 days.

Infection may be asymptomatic or may result in a mild self-limiting illness presenting with fever, malaise, upper respiratory tract symptoms and abdominal pain. Children often develop a bright red facial rash ('slapped cheek') 1 to 2 weeks later, followed after a few days by a light pink rash on the chest, stomach, arms and thighs. Adults have similar symptoms but are less likely to have a facial rash. Adults are also more likely to have joint pain (polyarthropathy), especially in the hands, wrists, feet and ankles. Rashes and joint pain can persist for several weeks or months after someone has recovered from the infection and do not prevent donation.

Individuals with parvovirus B19 are infectious during early stages of infection, before and while experiencing systemic and upper respiratory tract symptoms. Once a rash has appeared, an individual is no longer infectious through the respiratory route. People who have recovered from parvovirus B19 infection have lifelong immunity to the virus.

Parvovirus B19 may cause more serious illnesses, including transfusion-dependent anaemia and bone marrow failure (aplastic crisis) in non-immune individuals who are also immunocompromised. If acquired during pregnancy, parvovirus B19 may result in severe foetal anaemia (hydrops fetalis), miscarriage and stillbirth. Note that due to the potential risk of bone marrow failure in the context of umbilical cord blood (UCB) transplant, the standard deferral period after parvovirus B19 infection is necessarily much more stringent for UCB donors than for whole blood and components donors, with a recommendation to defer prospective UCB donors who have had parvovirus B19 infection at any time during the current pregnancy.

Although a drop in plasma viral load of several orders of magnitude is typically seen within 4 weeks of initial infection, viral DNA can remain detectable for months or years. Current knowledge indicates that after a certain period has elapsed from the point when peak viral load and peak IgG titres have been reached, parvovirus B19 virus infectivity in blood is unlikely. There is currently insufficient data to guarantee at which point transmission by hematopoietic progenitor cell transplant would not occur following a primary infection. In addition, there is limited data on the course of parvovirus B19 infection during pregnancy. It is therefore recommended that donors who have had confirmed parvovirus B19 infection at any time during the current pregnancy should be deferred on a precautionary basis.

Expert virologist advice should be sought for any cases with concerns over potential parvovirus B19 transmission risk.

Scenarios

Affected individual

Obligatory

Must not donate if:

The donor has had confirmed parvovirus B19 infection at any time during the current pregnancy.

Discretionary

If the infection was not during the current pregnancy and clinical symptoms, if present, have resolved, accept.

Close contact with an affected individual

Obligatory

Must not donate if:

Less than 3 weeks since contact with an individual with suspected or confirmed parvovirus B19 infection. This includes individuals diagnosed through blood donation screening.

Discretionary

1. If the donor has a definite past history of parvovirus B19 infection (IgG positive in a sample taken prior to the exposure), accept.
2. If any contact in the previous 3 weeks has only been with someone in the post-infectious phase (i.e. after the rash has appeared), accept.

Reason for change: This is a new entry.

Version details: CB-DSG Edition 203 Release 59 (6 October 2026)

Peptic ulcer

Cord Blood

Essential information

Includes	Gastric and duodenal ulcer and erosions.
Obligatory	Must not donate if: Associated with malignant change.

Supporting information

See if relevant	• Surgery • Transfusion
-----------------	---

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Perthes disease

Cord Blood

Essential information

Discretionary Accept.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Pituitary extract, human

Cord Blood

Essential information

Includes Adrenocorticotrophic hormone, follicle stimulating hormone, gonadotrophin, growth hormone, luteinising hormone, thyroid stimulating hormone.

Obligatory **Must not donate if:**
Has ever received injection(s) of human pituitary extract.

Supporting information

See if relevant

- [Growth hormone](#)
- [Prion-associated diseases](#)

Additional information Human pituitary extracts have been contaminated with abnormal prions and have led to the spread of Creutzfeldt-Jakob disease (CJD). They have been used to treat growth hormone deficiency and infertility. They have also been used in diagnostic tests to see if other endocrine glands such as the thyroid and adrenal work normally. They have not been used in the UK since 1985 and it is thought that all those exposed to these extracts have been notified of their increased risk of CJD. It is uncertain as to when their use stopped in other countries.

Donors that have been given only synthetic pituitary hormones or gonadotrophin made from urine may be accepted.

*Reason for change: Additional information has been added for clarity.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Platelet disorders

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Causes excessive bleeding or bruising and could be transmitted by stem cells.
2. Has thrombocytosis.

Supporting information

See if relevant

- [Haematological disease](#)
- [Immune thrombocytopenia](#)
- [Immune thrombocytopenia](#)

Additional information

Maternal platelet counts in excess of $500 \times 10^9/L$ should be repeated. If found to be persistently raised, the mother should not be accepted and referred for investigation.

*Reason for change: Thrombocytosis' and relevant links have been added.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Pleurisy

Cord Blood

Supporting information

- See if relevant
- [Infection, general](#)
 - [Malignancy](#)

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Pneumothorax

Cord Blood

Scenarios

Spontaneous pneumothorax

Discretionary Accept.

Traumatic pneumothorax

Obligatory See: [Accident](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Poisoning

Cord Blood

Essential information

Obligatory

Must not donate if:

There is evidence that the individual (donor/or mother of cord blood donor) has ingested, or been otherwise exposed to toxic substances that could be transmitted in donated material in dosages that could endanger the health of recipients.

Discretionary

If the individual is being monitored following exposure and the levels of the agent in question are within safe limits, accept.

Supporting information

See if relevant

- [Addiction and drug abuse](#)

Additional information

Advice may be sought from the National Poisons Information Service if required.

Regulatory information

This is a requirement of the Human Tissue Authority (HTA) [Guide to Quality and Safety Assurance for Tissues and Cells for Patient Treatment](#).

Reason for change: This is a new entry.

Version details: CB-DSG Edition 203 Release 28 (17 February 2018)

Polycythaemia

Cord Blood

Essential information

Obligatory	Must not donate.
Discretionary	If confirmed as secondary polycythaemia, accept.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Porphyria

Cord Blood

Essential information

Obligatory

Must not donate if:

Suffers from porphyria.

Discretionary

If the potential donor suffers from acute intermittent porphyria (AIP), varigate porphyria (VP) or hereditary coproporphyria (HCP), accept.

Supporting information

See if relevant

- [Hepatitis](#)

Additional information

Porphyria cutanea tarda (PCT) is almost always an acquired condition associated with underlying liver disease, usually hepatitis of viral or unknown origin.

Erythropoietic protoporphyria (EPP) and congenital erythropoietic porphyria (CEP) have porphyrins in the red cells causing the red cell life span to be reduced.

Reason for change: This is a new entry.

Version details: CB-DSG Edition 203 Release 10 (06 December 2011)

Post-viral fatigue syndrome

Cord Blood

Essential information

Includes Myalgic encephalopathy (ME), chronic fatigue syndrome (CFS).

Obligatory

Must not donate if:

1. Not resolved.
2. Affected during this pregnancy.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Pre- and post-exposure prophylaxis (PrEP, PEP) for HIV prevention

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Donor has taken oral pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) in the previous 3 months.
2. The donor has received an injection for PrEP in the previous 24 months.

Assess any donor using PrEP or PEP for tissue safety risks relating to sexual activity.

Discretionary

If:

- It is over 3 months since the donor last used oral PrEP or PEP, and/or
- It is over 24 months since the donor last received an injection for PrEP, and
- There is no other tissue safety risk,

accept.

Supporting information

See if relevant

- [HIV](#)
- [Inoculation injury](#)
- [Tissues safety](#)

Additional information

Pre-exposure prophylaxis (PrEP):

The use of PrEP to prevent HIV is increasing. Individuals taking PrEP are unlikely to be eligible to donate due to criteria within the [Tissues safety](#) entry. However, PrEP is also available via private prescription and/or online pharmacies and may be used by individuals who would not otherwise be deferred.

PrEP is normally given in tablet form but longer-acting injectable PrEP e.g. cabotegravir (Apretude®) may also be used in individuals who are not suitable for oral medication. Cabotegravir injections are given on an 8-weekly basis to ensure adequate HIV protection. Low levels of cabotegravir can be detected for many months in treated individuals, even after injections have been stopped.

Use of PrEP may interfere with testing for HIV by delaying seroconversion or giving unclear results in a positive donor. For this reason, it is important that donors who have taken oral PrEP in the previous 3 months, or injected PrEP in the previous 24 months, are not accepted to donate, even if they do not have another tissue safety risk.

Post-exposure prophylaxis (PEP):

PEP has a similar mechanism of action to PrEP and may also interfere with testing results. In the UK, PEP is prescribed to people who have been exposed to someone who may have HIV. This includes through sexual activity or exposure through a needle stick injury. Donors who have received PEP will usually be ineligible to donate for the same reason they were given PEP.

If the underlying reason for taking PrEP or PEP warrants a longer deferral period,

this should be applied.

*Reason for change: Addition of a 24-month deferral for recipients of injectable PrEP.
Version details: CB-DSG Edition 203 Release 56 (13 October 2025)*

Pregnancy

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Resulted in a malignant (invasive) hydatidiform mole.
2. Resulted in a non-malignant (non-invasive) hydatidiform mole and treatment and follow up is ongoing.

Supporting information

See if relevant

- [Surgery](#)
- [Transfusion](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Prion-associated diseases

Cord Blood

Essential information

Includes	Sporadic, familial and variant Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia.
Obligatory	Must not donate if: 1. Diagnosed with any form of CJD, or other human prion disease. 2. Identified at increased risk of developing a prion associated disorder. This includes: a. Individuals at familial risk of prion-associated diseases (have had 2 or more blood relatives develop a prion-associated disease or have been informed following genetic counselling they are at risk). b. Individuals who have been told that they have been put at increased risk from surgery, transfusion or transplant of tissues or organs. c. Individuals who have been told that they may be at increased risk because a recipient of blood or tissues that they have donated has developed a prion related disorder. d. Recipients of dura mater grafts. e. Recipients of corneal, scleral or other ocular tissue grafts. f. Recipients of human pituitary derived extracts. g. Since 1 January 1980: Recipients of any allogeneic human tissue.
Discretionary	If the mother has had 2 or more blood relatives develop a prion-associated disease and, following genetic counselling, they have been informed that they are not at risk, accept. This requires confirmation by a Designated Clinical Support Officer.

Supporting information

See if relevant	• Pituitary extract, human • Tissue and cell allograft recipients • Transfusion
Additional information	A Position Statement on Creutzfeldt-Jakob disease is available .
Regulatory information	This advice is a requirement of the EU Tissue and Cells Directive.

Reason for change: To reflect guidance from the Committee on the Microbiological Safety of Blood Tissues and Organs. There is the same concern over a possible second wave of cases of vCJD from accepting donors who have received tissue or organ transplants, as there is over donors who have been previously transfused.

Version details: CB-DSG Edition 203 Release 21 (18 January 2016)

Psoriasis

Cord Blood

Essential information

Obligatory

See: [Autoimmune disease](#) and [Immunosuppression](#)

Must not donate if:

1. Generalised or severe.
2. There is a secondary Infection.
3. Immunosuppressed.

Discretionary

1. If mild and only using topical treatment, accept.
2. If the donor is on immunosuppressive medication, see [Immunosuppression](#).

Supporting information

Additional information

Psoriasis is primarily a skin condition caused by an autoimmune process. About 1 in 10 people with psoriasis may develop joint problems (psoriatic arthropathy). Sometimes the disease is treated with powerful drugs to suppress the underlying autoimmune process. This may alter the body's defense mechanisms to infection.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 43 (16 March 2022)

Pulmonary embolism (PE)

Cord Blood

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Malignancy](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Pyrexia

Cord Blood

Also known as: fever

Scenarios

Not related to travel in malarious areas

Obligatory

Must not donate if:

Less than 2 weeks from an episode of pyrexia.

Discretionary

If related to a common cold or other upper respiratory tract infection from which the mother is now recovered or recovering, accept.

See if relevant

- [Infection, general](#)

Additional information

A raised temperature may be a sign of an infection, which could be passed on through a donation. Waiting 2 weeks from when the temperature returns to normal reduces the risk of infection being transmitted by the donation.

There is no evidence that common colds and upper respiratory tract infections can be passed on by donation but it is still necessary to wait until any such infection is obviously getting better before allowing donation.

Related to travel in malarious areas

Obligatory

See: [Malaria](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Pyruvate kinase deficiency (PKD)

Cord Blood

Essential information

Obligatory

Must not donate if:

Mother and father have symptomatic disease.

Discretionary

Unless mother and father both have symptomatic disease, accept.

Supporting information

Additional information

This is an autosomal recessive red cell enzyme deficiency that is variable in its severity. This means it only has relevance if both parents have symptomatic disease.

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Q fever

Cord Blood

Essential information

Obligatory  Must not donate.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Rabies

Cord Blood

Scenarios

Infection

- | | |
|-----------------|--|
| Obligatory | Must not donate. |
| See if relevant | • Animal bite, non-human |

Immunisation - post exposure

- | | |
|------------|---|
| Obligatory | Must not donate until:
At least 24 months post exposure and fully cleared by treating physician. |
|------------|---|

Immunisation - non-exposed

- | | |
|---------------|-------------------------|
| Discretionary | If non-exposed, accept. |
|---------------|-------------------------|

*Reason for change: To extend the deferral period post exposure to 24 months.
Version details: CB-DSG Edition 203 Release 37 (15 July 2020)*

Radiation therapy

Cord Blood

Essential information

Obligatory

Must not donate if:

For malignancy other than basal cell carcinoma.

For other treatments:

Refer to a Designated Clinical Support Officer.

Discretionary

1. If fully recovered and is acceptable according to immunosuppression advice, accept.
2. If for basal cell carcinoma or ductal carcinoma in situ of the breast, all treatment has been completed, the donor has been discharged from follow-up and is eligible under the [Malignancy](#) guideline, accept.

Supporting information

See if relevant

- [Basal cell carcinoma](#)
- [Immunosuppression](#)
- [Malignancy](#)

Additional information

Radiation therapy is sometimes used for non-malignant conditions, particularly for some skin conditions. It is often used as a substitute for other treatments that work by suppressing the immune system such as high dose steroids and cytotoxic drugs. More information is likely to be required before a decision can be made as to if an individual can donate. This why a referral to a Designated Clinical Support Officer is required.

Reason for change: Additional discretionary acceptance for basal cell carcinomas and ductal carcinoma in situ of the breast. A link had been added to autoimmune disease, and additional information has been added.

Version details: CB-DSG Edition 203 Release 27 (27 November 2017)

Radionuclides

Cord Blood

Essential information

Obligatory

1. **Radioactive iodine therapy:**
Must not donate if:
 - a. For malignancy.
 - b. Administered in this pregnancy or the preceding 6 months.
2. **Other treatment or investigation:**
Refer to a Designated Clinical Support Officer.

Supporting information

See if relevant

- [Malignancy](#)
- [Thyroid disease](#)

Additional information

In general, those used for diagnostic purposes are cleared within 24 hours. Some (e.g. radioactive iodine) have long half-lives and affected mothers must not be accepted.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Raynaud's syndrome

Cord Blood

Essential information

Obligatory	Must not donate if: Part of a multisystem disorder.
------------	--

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Recipients of normal human immunoglobulin

Cord Blood

Essential information

Obligatory

See: [Transfusion](#)

Supporting information

See if relevant

- [Hepatitis A](#)
- [Immunoglobulin therapy](#)
- [Immunosuppression](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Renal colic

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Symptomatic.
2. Under investigation.

Supporting information

See if relevant

- [Infection, general](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Respiratory disease

Cord Blood

Supporting information

- See if relevant
- [Infection, general](#)
 - [Steroid therapy](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Retinitis pigmentosa (RP)

Cord Blood

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Disabled mother](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Rheumatic fever

Cord Blood

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Infection, acute](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Rheumatoid arthritis (RA)

Cord Blood

Essential information

Obligatory

See: [Autoimmune disease](#)

Discretionary

If mild and the only treatment is nonsteroidal anti-inflammatory drugs (NSAIDs), accept.

*Reason for change: This entry is now linked to 'Autoimmune Disease'.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Ringworm

Cord Blood

Essential information

Obligatory	Must not donate if: On systemic treatment.
Discretionary	If on local treatment only, accept.

Supporting information

See if relevant

- [Infection, general](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Rubella

Cord Blood

Scenarios

Acute infection

Obligatory

See: [Infection, acute](#)

Contact with an infected individual

Obligatory

See: [Infectious diseases, contact with](#)

Congenital infection

Obligatory

Must not donate if:

Baby has congenital rubella.

Reason for change: This is a new entry.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Sarcoidosis

Cord Blood

Scenarios

Acute sarcoidosis

Obligatory

Must not donate if:

1. Not recovered.
2. Less than 5 years from both finishing all treatment and full recovery.

Discretionary

If more than 5 years since finishing all treatment and full recovery, accept.

Additional information

Acute sarcoidosis is normally a self-limiting disease and does not require treatment in about 90% of cases. The cause is not known but there appears to be an immune defect that can run in families. Because of the uncertainty with this condition, only potential donors who have fully recovered and been off all treatment for at least 5 years may donate.

Chronic sarcoidosis

Obligatory

Must not donate.

Additional information

Chronic sarcoidosis can cause a range of problems, particularly with the lungs but also with the heart, that may pose risks for a potential donor. The treatments used may also cause immunosuppression. For these reasons, people with this condition should not donate.

Reason for change: To align the guidance with that for blood donors, new guidance to accept donors who required treatment but who have made a full recovery and have been off all treatment for at least five years has been added. 'Additional Information' has been added.

Version details: CB-DSG Edition 203 Release 16 (31 March 2014)

Self-catheterisation

Cord Blood

Essential information

Obligatory  Must not donate.

Supporting information

Additional information Mothers who need to self-catheterise are likely to have bacteraemia following the procedure. Bacteria in a donation can lead to severe and even fatal reactions.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Sex worker

Cord Blood

Essential information

Definition/s	In this context, sex is defined as vaginal, oral or anal sex with or without a condom/protective.
Obligatory	Must not donate.
Discretionary	If 3 months or more has elapsed since the donor last received money or drugs for sex, accept.

Supporting information

See if relevant	• Addiction and drug abuse • Hepatitis of unknown origin • HIV • HTLV • Infection, general
Additional information	This guidance presumes that a validated NAT test for HIV, HBV and HCV is negative; if this test is stopped for any reason, the guidance will change. If received injectable drugs of addiction for sex, see Addiction and Drug Abuse entry as a 12-month deferral may apply.

Reason for change: This entry was updated in line with the recommendations of the SaBTO Donor Selection Criteria Review Report published on 23rd July 2017.

Version details: CB-DSG Edition 203 Release 51 (15 November 2023)

Sexually transmitted disease (STD)

Cord Blood

Supporting information

- See if relevant
- [Infection, acute](#)
 - [Infectious diseases, contact with](#)
 - [Herpes, genital](#)
 - [Syphilis](#)
 - [Tissues safety](#)
 - [Warts, genital](#)

Additional information Guidelines (NICE, BASHH) recommend that current sexual partners of lymphogranuloma venereum (LGV) probable or confirmed individuals should receive testing and empiric treatment with a chlamydial regimen. They can be accepted 3 months after completion of treatment.

Scenarios

Affected individual

Obligatory

See: is there is a specific [entry](#) for the disease?

Must not donate.

Discretionary

If fully treated, at least 3 months from completion of treatment, accept. Additionally, for gonorrhoea, evidence of a test of cure after treatment is required. This may be a verbal confirmation, provided by the donor.

Current or former sexual partner of an affected individual

Obligatory

See: is there is a specific [entry](#) for the disease with which there has been contact?

Must not donate if:

1. Mother required treatment and it is less than 3 months since completing that treatment.
2. Mother did not require treatment and it is less than 3 months from the last sexual contact with the infected partner.

Discretionary

1. Donor did not require treatment and it is more than 3 months since the infected partner has completed treatment, accept.
2. Donor required treatment: if fully treated, and if it is at least 3 months from completion of treatment, accept. Additionally, for gonorrhoea, evidence of a test of cure after treatment is required. This may be a verbal confirmation, provided by the donor.
3. If the donor's sexual partner has been diagnosed with chlamydia (except lymphogranuloma venereum, see **2** above), genital warts or genital herpes and the donor is asymptomatic and not undergoing treatment or investigation, accept.

Reason for change: 'See if Relevant' links have been updated.

Version details: CB-DSG Edition 203 Release 61 (13 October 2025)

Shingles

Cord Blood

Scenarios

Affected individual

Obligatory | See: [Herpes zoster](#)

Contact with an affected individual

Obligatory | See: [Infectious diseases, contact with](#)

*Reason for change: The links have been changed for clarity.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Sickle cell trait

Cord Blood

Essential information

Obligatory

Inform Transplant Centre if:

Cells are from a baby that has sickle cell trait.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Skin disease

Cord Blood

Essential information

Obligatory	Must not donate if: 1. The condition is infected or infectious. 2. Malignant.
Discretionary	If malignancy was a basal cell carcinoma and treatment is completed, accept.

Supporting information

See if relevant	• Dermatitis • Infection, general • Malignancy • Psoriasis
-----------------	--

*Reason for change: Malignancy' has been added to 'Obligatory' and additional links have been included.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Smallpox immunisation

Cord Blood

Scenarios

Immunised individual

Obligatory

Must not donate if:
Inoculated during pregnancy.

Additional information

Smallpox immunisation is with live virus. We do not want to pass the virus on to people receiving stem cells.

Contact with an immunised individual

Obligatory

Must not donate if:
Secondarily inoculated during this pregnancy.

Discretionary

If no new skin lesions, accept.

Additional information

Close contacts of vaccinees (household or direct bodily contact) may become secondarily infected from direct skin contact with an infected inoculation site or from virus on clothing, bedding, dressings etc. If infection occurs, a new skin rash, blister or sore appears at the site of contact, which could be anywhere on the body. The rash represents a secondary vaccination site and presents exactly the same potential risk to patients and staff as that of a person who has been intentionally immunised.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Snake bite

Cord Blood

Reason for change: This entry has been removed. Guidance on snake bites is now included in the 'Animal bite, non-human' entry, which now includes 'snake bite' as a search term.

Version details: CB-DSG Edition 203 Release 59 (6 October 2026)

South American trypanosomiasis

Cord Blood

Also known as: Chagas disease

Essential information

Obligatory  Must not donate.

Supporting information

See if relevant

- [South American trypanosomiasis, risk of](#)

*Reason for change: 'Chagas disease' added as an 'Also known as' term.
Version details: CB-DSG Edition 203 Release 57 (1 May 2026)*

South American trypanosomiasis, risk of

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Mother was born in South America or Central America (including Mexico).
2. Mother's mother was born in South America or Central America (including Mexico).
3. Has had a transfusion in South America or Central America (including Mexico).
4. Mother has lived and/or worked in rural subsistence farming communities in these countries for a continuous period of four weeks or more.

Discretionary

1. If at least 4 months from the date of last exposure, including transfusion abroad, and a validated *T. cruzi* antibody test is negative, accept.
2. Mother transfused since 1 January 1980:
Discuss with the Designated Clinical Support Officer who will decide if the donation may be accepted. The full transfusion history must be recorded and remain part of the documentation.

Supporting information

See if relevant

- [Geographical Disease Risk Index](#) for countries with a current *T. cruzi* risk
- [Transfusion](#)

Additional information

Infection with *T. cruzi* is very common in many parts of South or Central America and is often symptomless. It can be passed from an infected mother to her unborn baby and by transfusion. The insect that passes the infection on is only common in rural areas and the greater time that an individual has spent living in housing conditions with thatched roofs or mud lined walls which harbour the insect vector, the greater their risk of becoming infected. Testing is available and should be performed if there is a possibility of infection. Waiting 4 months from the last time of exposure allows time for the antibodies that are tested for to develop.

Camping or trekking in the jungle in South or Central America (including Mexico) is not considered of high enough risk to merit exclusion.

Reason for change: To reduce deferral period following last date of exposure from six to four months. To permit individual risk assessment if transfused after 1st January 1980. To also align this entry with the Geographical Disease Risk Index and change the reference to "Southern Mexico" to "Mexico".

Version details: CB-DSG Edition 203 Release 38 (07 October 2020)

Spina bifida

Cord Blood

Essential information

Obligatory

Must not donate if:

- 1. Has an indwelling shunt.
- 2. Uses a catheter.
- 3. Has a pressure sore.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Spinal surgery

Cord Blood

Supporting information

See if relevant

- [Neurosurgery](#)
- [Surgery](#)
- [Transfusion](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Splenectomy

Cord Blood

Essential information

Obligatory

Must not donate if:

1. For malignancy.
2. For a myeloproliferative disorder.
3. For immune thrombocytopenia (ITP).
4. For haemolytic anaemia.

Discretionary

1. If for trauma, when recovered, accept.
2. If taking prophylactic antibiotics, accept.
3. Discretions are available to accept donors with [haemolytic anaemia](#) and [immune thrombocytopenia](#).

Supporting information

See if relevant

- [Haemolytic anaemia](#)
- [Immune thrombocytopenia](#)
- [Malignancy](#)
- [Surgery](#)
- [Transfusion](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Steroid therapy

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Regularly taking steroid tablets, injections or enemas, or applying creams over large areas.
2. The mother has needed treatment to suppress an autoimmune condition in the last 12 months.
3. Less than 7 days after completing a course of oral or injected steroids for disorders associated with allergy.
4. The mother has infected perineal dermatitis.

Discretionary

1. If occasional use of creams over small areas of skin for minor skin complaints, accept.
2. If using steroid inhalers for prophylaxis, accept.
3. The short-term administration of steroids to the mother to induce fetal lung maturation is not an exclusion to donation, accept.

Supporting information

See if relevant

- [Autoimmune disease](#)
- [Skin disease](#)
- [Tissue and cell allograft recipients](#)

Additional information

Steroid therapy in high doses causes immunosuppression. This may mask infective and inflammatory conditions that would otherwise prevent donation.

There is no evidence that the short-term use of steroids to induce fetal lung maturation can mask or increase the risk of maternal infection.

Regulatory information

Part of this advice is a requirement of the EU Tissue and Cells Directive.

*Reason for change: To allow mothers who receive short term administration of steroids to induce fetal lung maturation to donate.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Stroke

Cord Blood

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Disabled mother](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Surgery

Cord Blood

Essential information

Definition/s	Major surgery: any surgical procedure resulting in an inability to return to normal activities of daily living (e.g. routine housework, previous employment and/or driving) for 6 months or more.
Obligatory	Must not donate if: 1. For malignancy. 2. All wounds are not healed. 3. There is any infection. 4. Normal mobility has not been regained. 5. Less than 6 months from major surgery. 6. Less than 7 days from other surgery. 7. Requiring post-operative treatment, or attending hospital regularly.
Discretionary	1. If for cervical carcinoma in situ (CIN) or basal cell carcinoma and all other criteria are fulfilled, accept. 2. If less than 6 months from major surgery or less than 7 days from other surgery, discuss with the Designated Clinical Support Officer who will decide if the mother may be accepted on a balance of risks.

Supporting information

See if relevant	• Basal cell carcinoma • Cervical dysplasia • Complementary therapy • Neurosurgery • Ocular surgery • Tissue and cell allograft recipients • Transfusion • Xenotransplantation
-----------------	--

Additional information	Surgery may place the mother at risk of infection, either from unhealed wounds or due to infection risks from infected staff or equipment. Although these risks are very small, it is important to wait long enough for the risks to have gone.
------------------------	---

*Reason for change: To align the 'Obligatory' and 'Discretionary' entries.
Version details: CB-DSG Edition 203 Release 41 (04 August 2021)*

Syphilis

Cord Blood

Scenarios

Affected individual

Obligatory

Must not donate.

Discretionary

If fully treated in the past and confirmatory tests exclude recent infection, discuss with a Designated Clinical Support Officer.

Additional information

The interpretation of syphilis testing is often difficult. The advice of an experienced microbiologist may be required before a decision on safety can be made.

Current or former sexual partner of an affected individual

Obligatory

Must not donate if:

1. The potential donor was diagnosed with syphilis (see **Affected individual** above).
2. It is less than 3 months since last sexual contact with an infected partner.

Discretionary

1. If it is more than 3 months from the last sexual contact with an infected partner, accept.
2. If it is more than 3 months since an infected partner has completed treatment, accept.

See if relevant

- [Tissues safety](#)

*Reason for change: The deferral period after sexual contact with an infected person has been reduced to three months.
Version details: CB-DSG Edition 203 Release 51 (15 November 2023)*

Systemic lupus erythematosus (SLE)

Cord Blood

Essential information

Obligatory  Must not donate.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Tamoxifen

Cord Blood

Essential information

Obligatory	See: Malignancy
Discretionary	If taken for non-malignant conditions, accept.

*Reason for change: To clarify that use of Tamoxifen for non-malignant conditions is not a contraindication to donation.
Version details: CB-DSG Edition 203 Release 38 (07 October 2020)*

Tetanus immunisation

Cord Blood

Essential information

Obligatory	Must not donate if: Less than 4 weeks from exposure.
Discretionary	If non-exposed, accept.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Therapeutic venesection

Cord Blood

Essential information

Obligatory	Must not donate.
Discretionary	If for haemachromatosis or confirmed secondary polycythaemia, accept.

Supporting information

See if relevant	Haemochromatosis
-----------------	--

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Threadworms

Cord Blood

Essential information

Discretionary Even if on treatment, accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Thrombocytosis

Cord Blood

Essential information

Obligatory	Must not donate if: Due to a myeloproliferative disorder.
------------	---

Supporting information

Additional information	Platelet counts in excess of $500 \times 10^9/L$ should be repeated. If found to be persistently raised, the donor should not be accepted and referred for investigation.
------------------------	---

*Reason for change: This entry has been added to clarify the eligibility of donors with this condition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Thrombosis

Cord Blood

Essential information

Discretionary If the underlying cause does not exclude, accept.

Supporting information

See if relevant • [Malignancy](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Thrush, oral

Cord Blood

Essential information

Obligatory	Must not donate if: 1. Unexplained. 2. Related to immunodeficiency.
------------	--

Supporting information

See if relevant	• Infection, chronic
-----------------	--

*Reason for change: This entry has been revised to link discretionary acceptance to the current 'Infection: Chronic' entry.
Version details: CB-DSG Edition 203 Release 41 (04 August 2021)*

Thrush, vaginal

Cord Blood

Essential information

Obligatory	Must not donate if: Related to immunodeficiency.
------------	---

Supporting information

See if relevant	Infection, chronic
-----------------	--

*Reason for change: This entry has been revised to link discretionary acceptance to the current 'Infection: Chronic' entry.
Version details: CB-DSG Edition 203 Release 41 (04 August 2021)*

Thyroid disease

Cord Blood

Essential information

Obligatory

Must not donate if:

1. Under investigation.
2. Malignant.
3. Radioactive iodine administered in this pregnancy or the preceding 6 months.
4. Less than 24 months from stopping treatment with anti-thyroid tablets.

Supporting information

See if relevant

- [Autoimmune disease](#)
- [Surgery](#)

Reason for change: The reference in 'Discretionary' to treatment with thyroxine has been removed. A link to 'Autoimmune Disease' has been added.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Tissue and cell allograft recipients

Cord Blood

Essential information

Excludes	Xenograft recipients, recipients of biological grafts of non-human origin and bio-prosthetic grafts, organ recipients.
Obligatory	All donors: Must not donate if: 1. Dura mater transplanted at any time. 2. Ocular tissue transplanted at any time. 3. Any other allogeneic human tissue or cell transplanted since 1 January 1980, refer to Designated Clinical Support Officer.
Discretionary	1. If an autologous tissue, or cells, has been transplanted at any time, and there is no other reason to exclude the donor, accept. 2. If an allogeneic tissue (except dura mater or ocular tissue) or cell transplant was performed before 1 January 1980, and there is no other reason to exclude the donor, accept.

Supporting information

See if relevant	• Immunosuppression • Ocular tissue recipient • Organ recipient • Prion-associated diseases • Surgery • Transfusion • Xenotransplantation
-----------------	---

Additional information	The transfer of tissues or cells between individuals has led to the spread of infection. The above guidelines are intended to minimise these risks. People who have received a tissue or cell transplant since 1980 are normally excluded from donation as a precautionary measure against the risk of transmission of variant Creutzfeldt-Jakob disease (vCJD) in the same way as recipients of transfusion are. The Designated Clinical Support Officer should consider the availability of alternative donors and discuss the risks and benefits with the physician of the intended recipient. This risk assessment should be shared with the recipient, or their next of kin as appropriate Dura mater and ocular tissue allografts have been implicated in iatrogenic CJD. Iatrogenic CJD refers to the transmission of prions via inadvertent medical exposure. Recipients of dura mater and ocular tissue recipients are excluded. Dura mater use stopped in the UK by 1993. The situation in other countries varied so specific dates cannot be given.
------------------------	---

Reason for change: This is a new entry.

Version details: CB-DSG Edition 203 Release 50 (04 July 2023)

Tissues safety

Cord Blood

Essential information

Definition/s

Individual risk is based on the donor's sexual behaviour, including new partners and the number of partners in the 3 months prior to donation.

Partner risk is based on sexual contact with a partner who may, at a population level, be at higher risk of acquiring infection, as described in this entry.

Sexual contact is defined as oral, vaginal or anal sex.

Anal sex is defined as penile-anal intercourse only. It does not apply to oro-anal sex or the use of sex toys.

Chemsex is sex while using stimulant drugs taken for the specific purpose of enhancing sexual experience and reducing inhibitions. Chemsex does not refer to sex after using alcohol or recreational drugs for other purposes, nor the use of drugs (e.g. Viagra® or Cialis®) to treat erectile dysfunction.

Obligatory

Information must be provided so that those at risk do not donate.

1. You must not donate if:

You think you need a test for HIV/AIDS, HTLV or hepatitis.

2. You must never donate if:

- a. You are HIV positive.
- b. You are HTLV positive.
- c. You are a hepatitis B carrier.
- d. You are a hepatitis C carrier.

3. You must not donate for at least 12 months:

After stopping habitual use of injected drugs of addiction.

4. You must not donate for at least 3 months if:

- a. You have taken pre-exposure prophylaxis (PrEP) / Truvada® by mouth to prevent HIV.
- b. You have taken or been prescribed post-exposure prophylaxis (PEP) by mouth to prevent HIV.

If the underlying reason for taking PrEP or PEP warrants a longer deferral period, this should be applied.

5. You must not donate for at least 24 months if:

You have received PrEP as an injection to prevent HIV e.g. cabotegravir (Apretude®).

If the underlying reason for taking PrEP or PEP warrants a longer deferral period, this should be applied.

6. You must not donate for at least 3 months if:

- a. You have received money or drugs for sex.
- b. You have injected, or been injected with, non-prescription drugs, even only once. This includes, for example, bodybuilding drugs or injectable tanning agents. You may be able to donate if a doctor prescribed the drugs. Please ask.
- c. You have injected, been injected with, or used non-parenteral chemsex drugs.

7. Individual risk criteria (FAIR):

You must not donate for at least 3 months if:

- a. You have taken part in chemsex activity, including the use of stimulant drugs. This risk applies for all sexual contact.
- b. You have been diagnosed with gonorrhoea. You must wait for at least 3 months after you have successfully completed treatment and been discharged from further follow-up.
- c. You have had more than 1 sexual partner in the last 3 months AND you have had anal sex with any of these partners.
- d. You have had anal sex with a new sexual partner. For the purpose of donor selection, a new partner is someone that you have not had sex with before or a previous partner with whom you have restarted a sexual relationship in the last 3 months.

If you are in a sexual relationship with 1 partner only, you can donate once it is 3 months from the date of first sexual contact, even if you are having anal sex.

8. You must not donate for at least 3 months after sex (even if you used a condom or other protective) with:

A partner who is, or you think may be:

- a. HIV or HTLV positive.
- b. A hepatitis B carrier.
- c. A hepatitis C carrier.
- d. A partner who has received money or drugs for sex.
- e. A partner who has injected, or been injected with, non-prescription drugs. This includes, for example, bodybuilding drugs or injected tanning agents. You may be able to give if a doctor prescribed the drugs, please ask.

Supporting information

See if relevant

- [Addiction and drug abuse](#)
- [Hepatitis B](#)
- [Hepatitis C](#)
- [Hepatitis of unknown origin](#)
- [HIV](#)
- [HTLV](#)
- [Infection, general](#)

- [Pre- or post-exposure prophylaxis for HIV prevention](#)
- [Sexually transmitted disease](#)
- [Syphilis](#)

Additional information

The For the Assessment of Individualised Risk (FAIR) report (2020) recommended changes to blood donor selection policy to allow a more individualised risk-based approach. This approach was approved by ministers in devolved administrations and has now been implemented by the UK Transfusion Services.

The FAIR III working group recommended that a similar approach could be applied to tissue and cell donors in principle, acknowledging that the current donor selection policies already permit an individual risk assessment approach for life saving tissues and cells.

FAIR identified several factors associated with a higher risk of blood borne infections. These include the recent diagnosis of a bacterial sexually transmitted disease and the following sexual behaviours:

- new or multiple sexual partners
- anal sex
- participation in chemsex activity

Drugs used for chemsex include methamphetamine, mephedrone and GHB/GBL, but other drugs may be used (e.g. ketamine, poppers, cocaine). Chemsex is a high risk activity because it usually involves multiple sexual partners, sometimes for extended periods of time. The drugs involved also reduce inhibition leading to riskier sexual activity.

The drugs used in both pre- and post-exposure prophylaxis for HIV (PrEP and PEP) may interfere with the routine HIV screening tests carried out on all tissue and cell donors. For this reason, donors who have taken oral PrEP or PEP in the previous 3 months, or received injectable PrEP in the previous 24 months, should not donate. This applies even if they are otherwise eligible under individual risk criteria.

The deferral periods specified above may be reduced by doing individual risk assessment if the risk of acquiring an infectious disease may be outweighed by the risk of delaying a lifesaving transplantation.

Reason for change: The entry was revised to include individual risk assessment of recent sexual behaviour for all donors. The deferral for donors whose sexual partners have been sexually active in Sub-Saharan Africa has been removed. This supports implementation of recommendations from the FAIR III Report.

Version details: CB-DSG Edition 203 Release 56 (13 October 2025)

Toxoplasmosis

Cord Blood

Essential information

Obligatory

Must not donate if:

Maternal recovery less than 6 months before this pregnancy.

Supporting information

Additional information

This is a common parasitic infection, often spread by cat faeces or eating undercooked meat. It can be spread through transfusion. It may have serious consequences or even prove fatal for the recipient. Usually it does not cause symptoms as the body's immune system easily overcomes the parasite. If the infection has caused symptoms that has led to it being diagnosed, waiting 6 months from recovery will make it unlikely that it will be passed on by donation.

A cord blood bank might undertake testing for toxoplasma, usually in the form of serological testing of the maternal donor. This is not a mandatory test, however it is recommended by SaBTO. The donation should not be released for clinical use if IgM positive.

Reason for change: To clarify that testing is not mandatory and that absence of a test is not a cause for deferral.

Version details: CB-DSG Edition 203 Release 41 (04 August 2021)

Transfusion

Cord Blood

Essential information

Includes

Treatment with blood components, products and derivatives.

Obligatory

1. Must not donate if:

At any time the mother has:

- Received, or thinks they may have received, a transfusion of blood or blood components in a country endemic for malaria or South American trypanosomiasis. See **Discretionary** for exceptions.
- Has received regular treatment with blood derived coagulation factor concentrates.
- Intrauterine transfusion has been required in this pregnancy.

2. Since 1 January 1980:

- Anywhere in the world, the mother has received, or thinks they may have received, a transfusion of blood or blood components, or intravenous or subcutaneous human normal immunoglobulin. This includes mothers whose babies have required intrauterine transfusion.
- Had a plasma exchange performed.

3. Before 1 January 1999:

Treated with prothrombin complex to reverse over-anticoagulation.

Discretionary

1. If:

- On medical inquiry, it is unlikely that the mother has been transfused, accept.
- Received, or thinks they may have received, a transfusion of blood or blood components before 1 January 1980, accept. See **3** below if transfused abroad.
- If treatment with human immunoglobulin has been limited to small quantities of specific immunoglobulin as prophylaxis (e.g. rhesus, tetanus, hepatitis, immunoglobulin etc.), accept.
- Treated with prothrombin complex (PCC) to reverse over-anticoagulation after 1 January 1999, accept.

2. Autologous transfusion:

If only the mother's own blood has been used, accept.

3. Mother transfused in a country endemic for malaria or South American trypanosomiasis:

Check the [Geographical Disease Risk Index](#). If transfused in an at-risk endemic country, and a validated malarial antibody test and/or (as appropriate) a validated test for *T. cruzi* antibody is negative, at least 4 months after exposure, accept. If transfusion happened after 1 January 1980, see **4** below.

4. Mother transfused since 1 January 1980:

Discuss with the Designated Clinical Support Officer who will decide if the

donation may be accepted. The full transfusion history must be recorded and remain part of the documentation.

Supporting information

See if relevant

- [Bleeding disorder](#)
- [Geographical Disease Risk Index](#)
- [Immunoglobulin therapy](#)
- [Immunosuppression](#)
- [Malaria](#)
- [Prion-associated diseases](#)
- [South American trypanosomiasis, risk of](#)

Additional information

Transfused donors have previously contributed to the spread of some diseases. This happened with hepatitis C.

All transfused mothers:

Transfusions in some countries may have put the donor at risk of malaria or South American trypanosomiasis. It is necessary to exclude these infections before accepting the donation.

Coagulation concentrates:

People who have received blood derived coagulation concentrates (these are made from the blood of many donors) regularly may have been put at risk of infections that can be passed through blood.

Mothers transfused since 1980:

In the autumn of 2003, a UK recipient of blood, taken from a healthy donor who later developed Creutzfeldt-Jakob disease (vCJD), died from vCJD. Since then there has been a very small number of cases of infection with the vCJD prion in recipients of blood from donors who have later developed vCJD. The risk of transplacental infection of a foetus with abnormal prion is not known but, even though it is thought to be small, cannot be ignored.

In view of this, mothers transfused or possibly transfused since 1980 should not normally be accepted. Any history of transfusion after 1980 must be recorded and remain part of the documentation associated with the donation.

Plasma exchange results in the patient having been exposed to multiple donors. In view of the increased vCJD risk, donations may not be taken from individuals who have had a plasma exchange performed since 1980.

Commonly used PCCs, such as Beriplex or Octaplex, currently used in the UK, are prepared from non-UK donors. They are administered as one-off doses to reverse anticoagulation or peri-operative prophylaxis. Since 1999, coagulation factors prepared from UK donors have no longer been used as a risk reduction measure for vCJD transmission.

Reason for change: I) To remove information only relevant to deceased tissue donors. II) To update guidance relating to South American Trypanosomiasis risk. III) To add guidance relating to mothers transfused since January 1st 1980. IV) To harmonise the

*definition of what constitutes a transfusion. V) Ensure consistent use of the term 'mother' rather than 'donor'.
Version details: CB-DSG Edition 203 Release 38 (07 October 2020)*

Travel

Cord Blood

Supporting information

See if relevant

- [Geographical Disease Risk Index](#)
- [Infection, tropical](#)
- [Malaria](#)
- [South American trypanosomiasis, risk of](#)

Reason for change: Entry carried over from previous Edition.

Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Trypanosoma cruzi infection

Cord Blood

Essential information

Obligatory Must not donate.

Supporting information

See if relevant

- [South American trypanosomiasis, risk of](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Tuberculosis (TB)

Cord Blood

Supporting information

- See if relevant
- [BCG](#)
 - [Heaf test](#)
 - [Mantoux test](#)

Scenarios

Affected individual

Obligatory

Must not donate if:

1. Infected.
2. Less than 24 months from completing treatment.
3. Under follow-up.

Discretionary

1. If mother with a history of tuberculosis or latent tuberculosis has been successfully treated, with treatment being completed at least 24 months previously, been discharged from follow-up, and has remained well and asymptomatic, accept.
2. Mothers with a diagnosis of latent tuberculosis currently not undergoing investigation, or more than 7 days after completion of treatment, refer to Designated Clinical Support Officer for individual risk assessment.

Contact with an affected individual

Obligatory

Must not donate until:

Screened and cleared.

Discretionary

If the mother has been informed that they do not need to be screened, accept.

Additional information

Tuberculosis (TB) can be present in many tissues and be spread through the blood stream. It is sensible to exclude mothers who may have active disease from donating to prevent any possibility of transmitting the infection.

Individuals with latent TB do not have symptoms of active infection. Treatment is usually recommended for individuals aged under 65. Antibiotics used to treat TB can cause liver damage in older adults, and hence treatment may not be offered. If latent TB is thought to be drug resistant, or if the individual is taking immunosuppressive medication for any reason, they may be regularly monitored to check the infection does not become active.

Reason for change: To provide clarity that 24 month deferral is following completion of treatment, rather than confirmation of cure. To provide information and guidance regarding latent tuberculosis.

Version details: CB-DSG Edition 203 Release 50 (04 July 2023)

Turner syndrome

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Vasculitis

Cord Blood

Essential information

Obligatory  Must not donate.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Viral haemorrhagic fever (VHF)

Cord Blood

Essential information

Includes Crimean-Congo Fever, Ebola Virus Disease, Lassa Fever, Marburg Fever.

Supporting information

See if relevant • [Geographical Disease Risk Index](#) for countries with a current endemic VHF risk

Additional information These infections have very high death rates and there is evidence that the virus may persist for some time after recovery. The 2014–2016 outbreak of Ebola in West Africa had increased understanding about the persistence of the virus in affected individuals and the number of asymptomatic individuals who may be able to transmit the virus to others.

There is no routine screening test for Ebola Virus (EBOV) currently available. There is an option to test donors serologically for the presence of anti-EBOV (antibodies) 2 months after the exposure event if a test becomes available. A reactive test would result in permanent deferral, a negative test would allow donation to proceed. Designated Clinical Support Officers may seek expert advice where necessary, under exceptional circumstances.

There is evidence of persistent virus in individuals who recover from several forms of viral haemorrhagic fever. For this reason, it is necessary to defer the sexual partners of these individuals.

Scenarios

Affected individual

Obligatory

Must not donate if:

Has ever been infected.

Contact with an affected individual or travel to endemic country

Obligatory

Must not donate if:

1. Was present in an area during an active outbreak.
2. Under investigation for viral haemorrhagic fever.
3. Has been in contact with an individual who was present in an area during an active outbreak.
4. Was in contact with an individual infected with, or was under investigation for viral haemorrhagic fever.
5. Less than 6 months after return to UK from an endemic area when there was no active outbreak.

Under exceptional circumstances, the donor may be accepted subject to individual risk assessment. Refer to Designated Clinical Support Officer. See **Additional information** below.

Discretionary

Accept if:

1. If more than 6 months after return to UK from an endemic area when there was no active outbreak at the time of visit.
2. If the individual, or the contact person, under investigation had viral

haemorrhagic fever infection excluded as diagnosis.

Sexual partner of an affected individual

Obligatory

Must not donate if:

The donor has had sex with an individual who had been diagnosed with a viral haemorrhagic fever at any time before their last sexual contact.

Reason for change: A permanent deferral has been introduced for donors who have had sex with an individual who has been diagnosed with a Viral Haemorrhagic Fever, and definition of Viral Haemorrhagic Fever provided.

Version details: CB-DSG Edition 203 Release 37 (15 July 2020)

Vitamin treatment

Cord Blood

Essential information

Discretionary Accept.

Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)

Warts

Cord Blood

Essential information

Discretionary Even if on local treatment, accept.

Supporting information

Additional information Warts (including verruca) are caused by infection with the human papillomavirus (HPV) of which there are over 100 different types. They may occur on the skin and mucous membranes. The virus is spread by skin-to-skin contact and it can be very infectious. Genital warts are possibly the commonest sexually transmitted disease, but they do not necessarily indicate high risk sexually activity, so no specific deferral is required.

 Molluscum contagiosum is also caused by a virus and can be managed in the same way as warts.

*Reason for change: 'Additional Information' section added following FAIR III report.
Version details: CB-DSG Edition 203 Release 51 (15 November 2023)*

Warts, genital

Cord Blood

Essential information

Discretionary Accept.

Supporting information

See if relevant • [Sexually transmitted disease](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Weight loss medication

Cord Blood

Essential information

Includes	Oral or injectable drugs for management of weight loss.
Excludes	Causes of obesity or related comorbidities. Donors with these conditions must be assessed using the relevant entries .
Obligatory	1. Oral medication Must not donate if: a. The medication used is itself a reason for deferral, or b. The donor is experiencing significant side-effects. 2. Injectable medication Must not donate if: a. Injectable medication has not been prescribed for the donor by a registered prescriber and/or has been obtained from a non-licensed source, or b. The donor is not using the medication as prescribed (e.g. sharing medication vials, pens or injection equipment with other users), or c. The donor is experiencing significant side-effects.
Discretionary	If: 1. The medication is not in itself a reason for deferral, and 2. The donor does not have significant side-effects, and 3. The medication has been prescribed for the donor by a registered prescriber and obtained from a licensed source, and 4. The donor is not sharing medication vials, pens or injection equipment, accept.

Supporting information

See if relevant	• Diabetes mellitus • Tissues safety
-----------------	--

Additional information	Several treatments for weight loss are licensed for use by the NHS including the oral medication orlistat (Alli®, Xenical®) and the injectable medications tirzepatide (Mounjaro®), liraglutide (Saxenda®) and semaglutide (Wegovy®). Donors prescribed any of these through an NHS provider can be accepted provided they are well and are using the medication correctly. It is important to check the entry for any underlying health conditions that the donor may have. Donors who are diabetic should be assessed using the Diabetes mellitus entry. Patients who are not eligible for NHS treatment may obtain weight loss medications from private providers. As long as the treatment has been prescribed by a registered healthcare professional, and issued through a licensed pharmacy, the donor can be accepted. Donors who have obtained injectable medication from a non-licensed source (including from friends or family) should not be accepted. It is important that donors who may be sharing medication vials, pens or injecting equipment are not accepted. Donors who have acquired treatments online can be accepted provided they meet the conditions outlined above. If staff are unsure whether a provider meets these
------------------------	---

criteria, refer to a Designated Clinical Support Officer.

Reason for change: This is a new entry.

Version details: CB-DSG Edition 203 Release 59 (6 October 2026)

West Nile Virus (WNV)

Cord Blood

Essential information

Definition/s	West Nile Virus (WNV) endemic areas are shown in the Geographical Disease Risk Index .
Obligatory	Must not donate if: 1. It is less than 6 months from a donor's return from a WNV endemic area and the donor has been diagnosed with WNV whilst there or following their return. 2. It is less than 6 months from a donor's return from a WNV endemic area and the donor has either had a history of symptoms suggestive of WNV whilst there or within 28 days of their return. 3. In other cases, it is less than 4 weeks from a donor's return from a WNV endemic area.
Discretionary	1. All donors may be accepted 6 months after their return from an affected area. This may be reduced to 4 weeks if they have had neither symptoms nor evidence of infection. For donors who have been back in the UK for less than 4 weeks, who have not been diagnosed with WNV infection and who have not had symptoms suggestive of WNV infection, if a validated NAT for WNV is to be undertaken on the donated component(s), accept. 2. Donors who have been back in the UK for less than 6 months, who have had symptoms suggestive of WNV infection while abroad or within 28 days of return, (but no firm diagnosis of WNV infection) if a validated NAT for WNV is to be undertaken on the donated component(s), accept.

Supporting information

See if relevant	• Geographical Disease Risk Index for countries with a current endemic WNV risk
Additional information	West Nile Virus is a flavivirus, similar to Dengue, which causes a wide spectrum of infection. This may range from no or minimal symptoms to death. It is geographically widespread, including areas in Europe and other parts of the world not affected by Malaria, and it has reached epidemic proportions in North America in recent years. There it has caused illness and death post transfusion and post transplantation of tissues and organs. It is spread by mosquitoes and so is more prevalent at times of the year when mosquitoes are active. As the problem can vary both in relation to geography and time of the year it is not possible to state areas from which donors need to be deferred and dates of disease activity. These are provided in the Geographical Disease Risk Index. A Position Statement on West Nile Virus is available.

Reason for change: To increase the deferral of donors following infection with West Nile Virus or symptoms suggestive of West

Nile Virus Infection to six months and to remove the requirement for a negative NAT test for these donors prior to donation.
Version details: CB-DSG Edition 203 Release 21 (18 January 2016)

Whooping cough

Cord Blood

Also known as: *pertussis*

Scenarios

Affected individual

Obligatory See: [Infection, acute](#)

Contact with an affected individual

Obligatory See: [Infectious diseases, contact with](#)

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Wilson's disease

Cord Blood

Essential information

Discretionary Accept.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Xenotransplantation

Cord Blood

Also known as: xenografts

Essential information

Definition/s	Xenotransplantation: any procedure that involves the transplantation, implantation, or infusion into a human recipient of either (a) live cells, tissues, or organs from a non-human animal source, or (b) human body fluids, cells, tissues, or organs that have had ex vivo contact with live, non-human animal cells, tissues, or organs. Xenotransplantation products include live cells, tissues and organs. Biological products, drugs, or medical devices sourced from non-living cells, tissues or organs from non-human animals, including but not limited to porcine insulin, porcine heart valves, and collagen matrices derived from acellular porcine, bovine or any other xenogeneic source (e.g. PelviSoft®, Bio-Oss®, Bio-Gide® and Surgibone®) are not considered xenotransplantation products.
Includes	Xenografts, heterografts, non-human organ perfusion.

Scenarios

Xenotransplant recipient

Obligatory	Must not donate if: Material from a living non-human animal source has been directly or indirectly in contact with the mother's blood supply. This does not include animal bites.
------------	---

Current or former sexual partner of a xenotransplant recipient

Obligatory	Must not donate.
Additional information	Exposure to non-human animal material, particularly when the person exposed is immunosuppressed, may result in infections that would not normally affect humans being passed on.

Reason for change: Further guidance re Recipient definition.
Version details: CB-DSG Edition 203 Release 23 (13 July 2016)

Xenotropic murine leukemia virus-related virus (XMRV)

Cord Blood

Essential information

Discretionary Donors who have been tested positive for XMRV, accept.

Supporting information

Additional information As there is no evidence that XMRV is implicated in human disease, a positive test is not a bar to donation.

Reason for change: This is a new entry.
Version details: CB-DSG Edition 203 Release 11 (24 January 2012)

Yaws

Cord Blood

Essential information

Obligatory  Must not donate.

*Reason for change: Entry carried over from previous Edition.
Version details: CB-DSG Edition 203 Release 02 (11 December 2007)*

Using these guidelines

Using these guidelines

Last updated in CB-DSG Edition 203 Release 57 (1 May 2026)

The Cord Blood Donor Selection Guidelines (CB-DSG) apply to donations of cord blood stem cells from placentae for therapeutic use.

The CB-DSG forms a constituent part of [Chapter 22](#) of the Guidelines for the Blood Transfusion and Tissue Transplantation Services in the UK.

JPAC is responsible for these guidelines and receives professional advice from its specialist Standing Advisory Committees and other relevant expert groups. The CB-DSG is primarily reviewed and updated by the Standing Advisory Committee on Cellular Therapy Products (SACCTP). It is reviewed regularly to ensure that donations are of the highest quality and of sufficient quantity to meet the needs of recipients.

Comments about the content of the CB-DSG, including notification of errors, omissions and suggestions for improvements, should be sent to JPACOffice@nhsbt.nhs.uk.

On this page

- General principles
- Use of the A to Z index
- Guideline terminology
- Medication
- Version control

General principles

Important

These guidelines are for healthcare professionals who are trained in their use.

JPAC cannot answer individual donor queries or provide personal medical advice. Help with such matters may be available through a local [blood and tissue service](#).

Donations must not be accepted from donors who exhibit health risks that are not listed in these guidelines without referral to, and acceptance by, a Designated Clinical Support Officer.

Cord blood is taken from the placenta of newborn infants. As placentae are normally treated as a waste product there is no risk to the infant or the mother. To ensure the donated material is safe to use it is important to exclude risk factors in the mother. On occasions, tests may need to be performed on the cord blood but no additional testing of the infant should be required. Unless stated specifically, all guidelines apply to the mother of the infant whose cord blood is collected.

Mothers are selected to ensure that their infant's cord blood stem cells are unlikely to harm any recipient.

The ultimate responsibility for the selection of donors rests with the Medical Director of each UK Blood and Tissue Service (UKBTS).

The immediate responsibility is with the Qualified Healthcare Professional who must ensure that the mother donor fulfills the respective selection criteria. When it is not clear from these guidelines if an individual donor is suitable, no donation should be taken without discussion with a Designated Clinical Support Officer.

The mother must be evaluated for their eligibility to donate their infant's cord blood by a Qualified Healthcare Professional who has undergone appropriate training to use these guidelines to select or defer a donor. They must verify their assessment by signing the donation record.

Special note must be taken of the content of the [Tissues safety](#) entry.

It is the responsibility of the Qualified Healthcare Professional to ensure that the mother clearly understands the nature of the donation process, the health check and other medical information presented to them. Mothers are asked about confidential aspects of their medical history, hence great care must be taken over privacy and confidentiality.

Use of the A to Z index

Any medical condition or possible contraindication to donation, elicited at any point during the donation process, must be managed as indicated by its respective guideline entry. A complete list of available entries can be found in the [A to Z index](#). Any collected material which, as a result, is unsuitable for clinical use must be clearly labelled as unfit for use.

If late information is provided by the mother, or through any other source, that the donation is medically unfit, this must be recorded and reported to the Designated Clinical Support Officer.

Any new health risks identified during the donor selection process should be notified to SACCTP so that they can be considered for incorporation into future revisions of the CB-DSG.

Guideline terminology

Please note, not all of the terms given below appear on every guideline entry.

Terms used for each section of an entry

Also known as	Alternative names for the entry.
Definition(s)	Clarification of key terms and concepts within the entry.
Includes	Any specific conditions, treatments or other factors covered by the entry.
Excludes	Any specific conditions, treatments or other factors not covered by the entry.
Obligatory	Reasons why a donor must not donate.
Discretionary	Reasons why a donor may be permitted to donate. These statements are conditional and all criteria that must be fulfilled will come before the final statement that they may be accepted. If the donor fulfils these requirements, as well as all others that apply, then they can be accepted.
See if relevant	Other guideline entries which may need to be consulted, depending upon the information provided by the donor.
Additional information	Further detail as to why any particular action is required.

Terms used within the text of an entry

Must not donate	The donor must not donate if any of the statements apply to them, unless a discretion clearly applies. If the deferral depends on time-related factors, the donor must be clearly advised when they will become eligible to donate again. If the deferral is not time limited (i.e. it is likely to be permanent) the donor must be clearly advised why they cannot donate.
See	The specified guideline entry must be consulted.
Refer to a Designated Clinical Support Officer	When there is a need to seek further advice, the Designated Clinical Support Officer is a suitably trained person authorised to undertake this task by the Medical Director or their nominated deputy.

Information provided at the end of each entry

Reason for change	A brief summary of the most recent changes to the entry.
Version details	The Edition and Release number of the current version of the entry and its date of publication.
Document	A link to the relevant Change Notification detailing the most recent update to the entry, if applicable.

Medication

The underlying illness suffered by a donor, rather than the properties of any drug they are taking, is the usual reason for an ineligibility to donate.

In general, traces of drugs in donations are harmless to their recipients. However, donors treated with certain drugs are deferred for periods associated with the pharmacokinetic properties of the drug. Examples are drugs used to treat acne, psoriasis, and some prostate problems. All such drugs have their own [entry](#).

Version control

The CB-DSG is under the continuing review of SACCTP and the Standing Advisory Committee on Transfusion Transmitted Infection (SACTTI) to ensure that they are accurate and up to date.

All changes are the responsibility of the Professional Director of JPAC and have the approval of the Executive Working Group (EWG) and the JPAC Board.

Terms used for version control of the guidelines

Change Notification	This notifies the Medical Director and the Quality Manager of each of the four UKBTS to upcoming changes to the guidelines. The implementation of any changes is the responsibility of the individual Services.
Edition	An extensive revision of the entire set of guideline entries.
Release	Changes to the one or more entries in the current Edition of the guidelines

Issue	which involve a change to the medical or scientific content.
	• Changes to the one or more entries in the current Release of the guidelines which have been made to correct an error or omission, or • Subsequent changes to the medical or scientific content of additional entries in an upcoming Release that has already been made available prior to publication Each Release of the guidelines will be Issue 1 unless otherwise stated on the Source files page.

The Quality Manager of each UKBTS will be notified of upcoming changes by electronic distribution of a Change Notification.

The Quality Manager is responsible for effecting changes to locally held copies of the guidelines, or to information adapted from the guidelines for use within their respective service. An effective version control and change procedure must be in place to ensure only current versions of the guidelines are in use and that all authorised copies, electronic and paper, are traceable.

Live version of the guidelines (this website)

The website will always display the current version of each guideline entry, as shown in the [A to Z index](#), and each entry will show the date of its most recent update. Changes will be published on the website on the effective date given in the relevant Change Notification.

Offline version of the guidelines (source files)

A source file is a downloadable copy of the guidelines. A source file containing the current version of the guidelines is always available on the [Source files](#) page.

In addition, whenever a Change Notification is distributed to indicate upcoming changes, an updated source file incorporating those changes will be made available. This will supersede the current source file on the effective date of the Change Notification and any previous source files will be removed.

Updates

Updates

The following table lists all updates to Edition 203 of the Cord Blood Donor Selection Guidelines (CB-DSG). The linked Change Notification documents were issued to the UK Blood and Tissue Services (UKBTS) to indicate upcoming changes.

Please note that the dates listed below indicate the formal publication of updated guidelines on the website. The implementation of these guideline changes is the responsibility of each UKBTS and may vary accordingly.

For changes pending publication, see [Upcoming changes to the guidelines](#).

Change number	Title	Updated	Guidelines affected	Release
12-2026	Mosquito-borne viruses (PDF only, 454KB)	11 August 2026	Geographical index Whole blood Tissue (deceased) Tissue (live) Bone marrow Cord blood	578166626058
09-2026	Changes to be introduced on the new JPAC website (PDF only, 864KB)	1 May 2026	Geographical index Whole blood Tissue (deceased) Tissue (live) Bone marrow Cord blood	568065625957
10-2026	Changes to entries in the GDRI and DSGs (PDF only, 418KB)	1 May 2026	Geographical index Whole blood Tissue (deceased) Tissue (live) Bone marrow Cord blood	568065625957
30-2025	Hepatitis A (PDF only, 205KB)	30 October 2025	Bone marrow Cord blood	5856
32-2025	Sexually Transmitted Disease (PDF only, 197KB)	13 October 2025	Bone marrow Tissue (deceased) Tissue (live) Cord blood	58646156
22-2025	Injectable Pre-Exposure Prophylaxis (PrEP) for HIV prevention (PDF only, 293KB)	13 October 2025	Tissue (deceased) Tissue (live) Bone marrow Cord blood	64615856
09-2025	Table of Immunisations (PDF only, 578KB)	30 April 2025	Whole blood Tissue (live) Tissue (deceased) Cord blood Bone marrow	7660635557
10-2024	Coronavirus	18 April 2024	Tissue	60575554

	Vaccination (PDF only, 311KB)		(deceased)Tissue (live)Bone marrowCord blood	
35-2023	Eye Disease (PDF only, 219KB)	29 January 2024	Bone marrowCord blood	5453
17-2023	FAIR III changes (PDF only, 605KB)	15 November 2023	Tissue (deceased)Tissue (live)Bone marrowCord blood	57555251
33-2023	Coronavirus Infection (PDF only, 378KB)	15 November 2023	Tissue (deceased)Tissue (live)Bone marrowCord blood	58565352
14-2023	Tissue and Organ Recipients (PDF only, 247KB)	4 July 2023	Tissue (deceased)Tissue (live)Bone marrowCord blood	56545150
25-2023	Tuberculosis (PDF only, 232KB)	4 July 2023	Tissue (deceased)Tissue (live)Bone marrowCord blood	56545150
13-2023	Mpox (Monkeypox) (PDF only, 313KB)	12 April 2023	Tissue (deceased)Tissue (live)Bone marrowCord blood	54525049
51-2022	Coronavirus Infection (COVID-19) (PDF only, 217KB)	13 December 2022	Tissue (deceased)Tissue (live)Bone marrowCord blood	53514948
52-2022	Infectious Diseases, Contact with (PDF only, 240KB)	13 December 2022	Tissue (deceased)Tissue (live)Bone marrowCord blood	53514948
55-2022	Table of Immunisations (PDF only, 156KB)	30 August 2022	Tissue (deceased)Tissue (live)Bone marrowCord blood	52504847
35-2022	Animal Bite (PDF only, 92KB)	31 May 2022	Cord blood	46
37-2022	Malaria (PDF only, 138KB)	31 May 2022	Cord blood	46
41-2022	Monkeypox (PDF only, 133KB)	31 May 2022	Tissue (deceased)Tissue (live)Bone marrowCord blood	51494746
30-2022	Coronavirus Infection (PDF only, 239KB)	7 April 2022	Tissue (deceased)Tissue (live)Bone	49474544

			marrowCord blood	
13-2022	Infertility (PDF only, 137KB)	16 March 2022	Tissue (deceased)Tissue (live)Bone marrowCord blood	48464443
14-2022	Psoriasis (PDF only, 152KB)	16 March 2022	Tissue (deceased)Tissue (live)Bone marrowCord blood	48464443
15-2022	Body Piercing (PDF only, 130KB)	16 March 2022	Tissue (deceased)Tissue (live)Bone marrowCord blood	48464443
16-2022	Cervical Dysplasia, Carcinoma In Situ, Cervical Cone Biopsy, Laser Treatment (PDF only, 152KB)	16 March 2022	Tissue (deceased)Tissue (live)Bone marrowCord blood	48464443

Appendices

Appendix 1: Medical criteria for the withdrawal of donations following information received after donation

Last updated in CB-DSG Edition 203 Release 02 (11 December 2007)

General considerations

Circumstances that should have excluded donation may only become known after cord blood has been taken. For the purposes of these guidelines, these circumstances are categorised below, along with appropriate actions.

The action to be taken will be determined by any [entry](#) relevant to the safety of the recipient. If there is no relevant entry, a consideration of recipient safety will underlie the action taken.

Procedures must be maintained by all UK Blood and Tissue Services to ensure prompt reporting of late donation information and, if necessary, withdrawal of donated cord blood. Concerns arising from hearsay reports should be addressed by procedures established to ascertain the credibility of any such concerns.

If donations have been used before a withdrawal could be initiated, the Designated Clinical Support Officer must decide upon appropriate action. This will include, if there are likely to be severe consequences from having received the stem cell transplant, contacting the clinician caring for the recipient and discussing notification of the recipient.

Late notification of donation test results

Late notification may occur because:

- The results of microbiological screening tests are brought into question.
- Additional information becomes available (e.g. the results of further testing).
- It is discovered that testing was not performed within the agreed procedures (e.g. as a result of audit or notification of defective reagents by the manufacturer).
- A report is received from the recipient's medical attendants of a post-transplant infection thought to have been transmitted by the donation.

Action: Inform the Designated Clinical Support Officer.

Notification of circumstances that should have triggered deferral at the time of donor selection

Circumstances include:

- Circumstances which place a mother at risk of infection with blood borne organisms (see [Tissues safety entry](#)).
- Mothers in the 'at risk' categories relating to possible transmission of prion-associated diseases e.g. Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD).
- Mothers with malignancy (other than those for which there is a discretion in the [CB-DSG](#)).
- Autoimmune disease.
- Mothers with certain infectious diseases at the time of donation or who were in contact with and still

within the incubation period of an infectious disease at the time of donation.

- Mothers with diseases of unknown aetiology.

Action: Inform the Designated Clinical Support Officer.

Appendix 2: Immunisations

Last updated in CB-DSG Edition 203 Release 55 (30 April 2025)

This appendix gives information on [live immunisations](#) and [non-live immunisations](#) that may have been received by potential donors.

Disease	Comments and example adult preparations	Immunisation type
Anthrax	Rarely given	Non-live
Cholera	Two cholera vaccines are available: Vaxchora® and Dukoral® ; see rows below. Ensure the correct guidance is applied depending on the vaccine given. If vaccine name not certain, treat as a live vaccine.	See below
Cholera	Vaxchora®	Live
Cholera	Dukoral®	Non-live
COVID-19 (SARS-CoV-2)	All COVID-19 vaccines licensed in the UK are non-live	Non-live
Dengue	Qdenga® , Dengvaxia®	Live
<i>Haemophilus influenza</i> type b (Hib)	Menitorex®	Non-live
Hepatitis A	May be combined with typhoid or hepatitis B. Hepatitis A only: Vaqta® , Avaxim® , Havrix® Combined with typhoid: ViATIM® Combined with hepatitis B: Ambirix® , Twinrix®	Non-live
Hepatitis B	May be combined with hepatitis A. If unexposed and more than 7 days from last immunisation, accept (see Hepatitis B). Engerix® , Fendrix® , HBvaxPRO® , PreHevBri® , Ambirix® , Twinrix®	Non-live
Human papillomavirus (HPV)	Cervarix® , Gardasil®	Non-live
Influenza, intra-nasal	Given by intra-nasal spray, from 2 to 18 years of age. Fluenz Tetra®	Live
Influenza, injection	This is the annual 'flu jab', given by	Non-live

	injection. Several preparations, updated annually.	
Japanese encephalitis	Usually given for travel. Ixiaro®	Non-live
Measles, mumps, rubella	This is the 'MMR' vaccine. M-M-RvaxPro®, Priorix®	Live
Meningitis	Meningococcal group C: NeisVac-C®, Menjugate Kit® Meningococcal group B: Bexsero®, Trumenba® MenACWY Quadrivalent vaccine: Menveo®, Nimenrix®, MenQuadfi® Combined with H. influenzae type b (Hib): Menitorix®	Non-live
Mpox	Imvanex® (MVA-BN) is a live attenuated non-replicating smallpox vaccine. It may be used for pre-exposure mpox prophylaxis in healthcare workers or for post-exposure prophylaxis in contacts of mpox cases. If given for mpox vaccination, treat as a non-live vaccine (see Mpox).	Non-live
Pertussis	Usually given to pregnant women, in combination with diphtheria/tetanus/polio vaccine or diphtheria/tetanus vaccine.	Non-live
Pneumococcal disease	Usually given to people with specific risks (e.g. people who have had a splenectomy, people over 65). Pneumovax 23®	Non-live
Polio, injected	Usually given in combination with other vaccines including (depending on the preparation) diphtheria, tetanus, pertussis and <i>Haemophilus influenzae</i> .	Non-live
Polio, oral	Not in routine use in the UK but may be given abroad	Live
Rabies	Usually given to non-exposed individuals if occupation or activity has an exposure risk, or for some travellers to endemic areas. Rabipur®, Verorab®	Non-live
Respiratory syncytial virus (RSV)	Abrysvo®, Arexvy®	Non-live
Shingles	Two shingles vaccines are available: Zostavax® and Shingrix®; see rows below. Please note, Shingrix® has replaced Zostavax® in the UK vaccination	See below

	programme for individuals aged 60-79 years.	
Shingles	Zostavax® for shingles prevention	Live
Shingles	Shingrix® for shingles prevention	Non-live
Smallpox	This requires an 8-week deferral. If given, see Smallpox immunisation. See also Mpox (above).	Live
Tetanus	Usually given in combination with other vaccines including (depending on the preparation) diphtheria, tetanus, pertussis and <i>Haemophilus influenzae</i> .	Non-live
Tick-borne encephalitis (TBE)	TicoVac®	Non-live
Tuberculosis	This is the 'BCG' vaccine	Live
Typhoid, injected	As a single preparation: Typhim Vi® Combined with hepatitis A: ViATIM®	Non-live
Typhoid, oral	Usually given in capsule form. Vivotif®	Live
Varicella (chickenpox)	Usually given to healthcare workers. Varilrix®, Varivax®	Live
Yellow Fever	Stamaril®	Live